Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID BERZ

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1437375128
CMS profile
110998
Location
LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$85,243.80

138 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID BERZ

NPI 1437375128 · CMS profile ID 110998

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1437375128?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID BERZ, NPI 1437375128, CMS profile ID 110998. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1437375128?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). DAVID BERZ, NPI 1437375128, CMS profile ID 110998. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1437375128?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
DAVID BERZ, NPI 1437375128, CMS profile ID 110998, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1437375128?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

138 matching records · $85,243.80 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 138 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–138 of 138.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $24.6906/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848163599 CMS
Amgen Inc. $24.3906/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825264487 CMS
Karyopharm Therapeutics Inc. $30.2706/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845784377 CMS
Bayer HealthCare Pharmaceuticals Inc. $20.7506/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789065703 CMS
Pharmacyclics LLC, An AbbVie Company $21.1406/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781008319 CMS
Boehringer Ingelheim International GmbH $119.4806/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 822296013 CMS
Boehringer Ingelheim International GmbH $278.0506/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 822296017 CMS
AstraZeneca Pharmaceuticals LP $268.8505/26/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829361837 CMS
AstraZeneca Pharmaceuticals LP $121.6705/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829525983 CMS
AstraZeneca Pharmaceuticals LP $947.3705/26/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829978381 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $1,600.0005/25/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851873515 CMS
Bayer HealthCare Pharmaceuticals Inc. $19.7505/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789085941 CMS
Exelixis Inc. $30.3805/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838869193 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $9.4205/12/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763334106 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $1,600.0005/12/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851873513 CMS
Merck Sharp & Dohme Corporation $24.6905/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848420183 CMS
Genentech USA, Inc. $23.2505/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835903771 CMS
AstraZeneca Pharmaceuticals LP $250.0005/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829969547 CMS
JAZZ PHARMACEUTICALS INC. $2,385.0005/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845602665 CMS
JAZZ PHARMACEUTICALS INC. $3,710.0004/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845606257 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $4,500.0004/15/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851873511 CMS
JAZZ PHARMACEUTICALS INC. $122.9204/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845603701 CMS
AstraZeneca Pharmaceuticals LP $24.0004/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829556117 CMS
Daiichi Sankyo Inc. $25.0004/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836281177 CMS
Bayer HealthCare Pharmaceuticals Inc. $21.8103/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789068287 CMS
Merck Sharp & Dohme Corporation $48.1603/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848463819 CMS
Genentech USA, Inc. $19.5303/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835903767 CMS
PUMA BIOTECHNOLOGY, INC. $29.8502/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834094253 CMS
Boehringer Ingelheim International GmbH $323.1502/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 822295815 CMS
JAZZ PHARMACEUTICALS INC. $1,590.0002/17/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845601695 CMS
Genentech USA, Inc. $24.3802/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835903765 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $5,625.0002/03/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851873519 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $161.0001/20/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851873521 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $213.8301/20/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851873523 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $96.3601/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851873525 CMS
Genentech USA, Inc. $19.4401/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835903761 CMS
AstraZeneca Pharmaceuticals LP $250.0001/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829290241 CMS
BeiGene USA, Inc. $33.6001/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846699253 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $100,892.10 230
PY2020 $59,743.88 73
PY2021 $85,243.80 138
PY2022 $101,453.02 192
PY2023 $60,514.66 155
PY2024 $10,874.41 103
PY2025 $1,242.80 48

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,065.52 3
PY2025 Principal investigator $22,570,156.96 3,127
PY2024 Principal investigator $11,954,256.94 1,800
PY2023 Principal investigator $4,769,303.07 1,104
PY2022 Principal investigator $2,622,889.08 553
PY2021 Principal investigator $743,277.94 102
PY2020 Principal investigator $185,286.26 9
PY2019 Principal investigator $60,123.89 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

3,130 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $133.41 12/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704453
Principal investigator 1 Boehringer Ingelheim International GmbH $133.41 12/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704455
Principal investigator 1 Incyte Corporation $99.00 12/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611385
Principal investigator 1 Incyte Corporation $4,131.00 12/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611407
Principal investigator 1 Incyte Corporation $506.00 12/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611428
Principal investigator 1 Incyte Corporation $107.00 12/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611462
Principal investigator 1 Incyte Corporation $107.00 12/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611465
Principal investigator 1 Incyte Corporation $107.00 12/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611469
Principal investigator 1 Incyte Corporation $107.00 12/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611473
Principal investigator 1 Incyte Corporation $58.00 12/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611501
Principal investigator 1 Incyte Corporation $819.95 12/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611643
Principal investigator 1 Incyte Corporation $80.00 12/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611730
Principal investigator 1 Incyte Corporation $80.00 12/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611734
Principal investigator 1 Incyte Corporation $80.00 12/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611740
Principal investigator 1 Incyte Corporation $171.00 12/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611912
Principal investigator 1 Incyte Corporation $171.00 12/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611919
Principal investigator 1 Incyte Corporation $371.00 12/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611931
Principal investigator 1 Incyte Corporation $2,351.70 12/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612294
Principal investigator 1 Incyte Corporation $50.00 12/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612385
Principal investigator 1 Incyte Corporation $2,352.45 12/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612423
Principal investigator 1 Incyte Corporation $242.00 12/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612512
Principal investigator 1 Incyte Corporation $70.00 12/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612517
Principal investigator 1 Incyte Corporation $70.00 12/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612519
Principal investigator 1 Incyte Corporation $70.00 12/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612522
Principal investigator 1 Incyte Corporation $63.00 12/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612580
Principal investigator 1 Incyte Corporation $84.00 12/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612584
Principal investigator 1 Incyte Corporation $84.00 12/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612587
Principal investigator 1 Incyte Corporation $45.00 12/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612840
Principal investigator 1 Incyte Corporation $1,845.95 12/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612858
Principal investigator 1 Incyte Corporation $74.00 12/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612921
Principal investigator 1 ABBVIE INC. $3,186.00 12/30/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202532256
Principal investigator 1 BeOne Medicines Ltd. $11,756.07 12/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190336063
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $7,087.67 12/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220996852
Principal investigator 1 Incyte Corporation $9,920.00 12/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611403
Principal investigator 1 Incyte Corporation $3,051.00 12/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611720
Principal investigator 1 Incyte Corporation $4,523.94 12/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611767
Principal investigator 1 Incyte Corporation $1,845.00 12/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611937
Principal investigator 1 Incyte Corporation $1,894.00 12/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611966
Principal investigator 1 Incyte Corporation $2,978.00 12/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612005
Principal investigator 1 Incyte Corporation $2,896.00 12/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612369
Principal investigator 1 Incyte Corporation $3,487.00 12/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612395
Principal investigator 1 Incyte Corporation $3,487.00 12/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612398
Principal investigator 1 Incyte Corporation $6,278.00 12/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612407
Principal investigator 1 Incyte Corporation $2,807.00 12/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612419
Principal investigator 1 Incyte Corporation $2,079.18 12/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612464
Principal investigator 1 Incyte Corporation $2,681.00 12/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612692
Principal investigator 1 Incyte Corporation $2,681.00 12/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612697
Principal investigator 1 Incyte Corporation $4,242.00 12/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612708
Principal investigator 1 Incyte Corporation $2,090.00 12/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612862
Principal investigator 1 Incyte Corporation $3,187.00 12/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612868
Principal investigator 1 Incyte Corporation $769.57 12/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612887
Principal investigator 1 Janssen Research & Development, LLC $80,688.00 12/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175413910
Principal investigator 1 Merck Sharp & Dohme LLC $1,004,440.00 12/29/2025 Non-covered Recipient Entity
Valkyrie Global, Inc.
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX 106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1232932041
Principal investigator 1 Janssen Research & Development, LLC $99,009.00 12/26/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175413845
Principal investigator 1 Janssen Research & Development, LLC $2,500.00 12/25/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175413815
Principal investigator 1 ABBVIE INC. $379.62 12/23/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202531766
Principal investigator 1 ABBVIE INC. $175.19 12/23/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202531768
Principal investigator 1 ABBVIE INC. $167.22 12/23/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202531770
Principal investigator 1 ABBVIE INC. $421.97 12/23/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202531844
Principal investigator 1 Daiichi Sankyo Inc. $177.00 12/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389771
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 12/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389785
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 12/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389815
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 12/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389823
Principal investigator 1 Janssen Research & Development, LLC $20,560.00 12/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175413960
Principal investigator 1 PFIZER INC. $24,273.44 12/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228715313
Principal investigator 1 BioNTech SE $2,849.00 12/19/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012697
Principal investigator 1 BioNTech SE $4,213.00 12/19/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012705
Principal investigator 1 BioNTech SE $2,849.00 12/19/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012747
Principal investigator 1 BioNTech SE $4,213.00 12/19/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012869
Principal investigator 1 BioNTech SE $3,931.00 12/19/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012877
Principal investigator 1 BioNTech SE $324.00 12/19/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012889
Principal investigator 1 Genentech, Inc. $13,370.00 12/19/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211682018
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,709.55 12/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804796
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,709.55 12/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804798
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $21,942.90 12/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804800
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,709.55 12/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804802
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,615.00 12/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804804
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,709.55 12/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804806
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $17,093.70 12/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804808
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,253.70 12/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804811
Principal investigator 1 Daiichi Sankyo Inc. $185.00 12/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388413
Principal investigator 1 Daiichi Sankyo Inc. $2,801.00 12/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388431
Principal investigator 1 Daiichi Sankyo Inc. $675.00 12/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388435
Principal investigator 1 Daiichi Sankyo Inc. $2,801.00 12/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388453
Principal investigator 1 Daiichi Sankyo Inc. $405.00 12/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388459
Principal investigator 1 Daiichi Sankyo Inc. $85.00 12/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388483
Principal investigator 1 Daiichi Sankyo Inc. $185.00 12/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388493
Principal investigator 1 PFIZER INC. $2,000.00 12/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228715243
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $254.55 12/17/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220996822
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $186.56 12/17/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220996824
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $159.84 12/17/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220996826
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $25.50 12/17/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220996828
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $14,515.85 12/17/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220996854
Principal investigator 1 Daiichi Sankyo Inc. $641.00 12/17/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388481
Principal investigator 1 Incyte Corporation $222.86 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611399
Principal investigator 1 Incyte Corporation $3,040.00 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611508
Principal investigator 1 Incyte Corporation $3,040.00 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611511
Principal investigator 1 Incyte Corporation $3,040.00 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611515
Principal investigator 1 Incyte Corporation $750.00 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611562
Principal investigator 1 Incyte Corporation $300.00 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611581
Principal investigator 1 Incyte Corporation $900.00 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611616
Principal investigator 1 Incyte Corporation $6,449.14 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611629
Principal investigator 1 Incyte Corporation $3,561.12 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611665
Principal investigator 1 Incyte Corporation $4,523.94 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611873
Principal investigator 1 Incyte Corporation $4,523.94 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611877
Principal investigator 1 Incyte Corporation $4,523.94 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611882
Principal investigator 1 Incyte Corporation $4,523.94 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611885
Principal investigator 1 Incyte Corporation $5,494.96 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611934
Principal investigator 1 Incyte Corporation $175.00 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611978
Principal investigator 1 Incyte Corporation $1,200.00 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611993
Principal investigator 1 Incyte Corporation $600.00 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612015
Principal investigator 1 Incyte Corporation $6,465.97 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612097
Principal investigator 1 Incyte Corporation $6,465.97 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612100
Principal investigator 1 Incyte Corporation $6,465.97 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612104
Principal investigator 1 Incyte Corporation $6,465.97 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612108
Principal investigator 1 Incyte Corporation $3,552.94 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612134
Principal investigator 1 Incyte Corporation $3,552.94 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612139
Principal investigator 1 Incyte Corporation $3,552.94 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612143
Principal investigator 1 Incyte Corporation $3,552.94 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612147
Principal investigator 1 Incyte Corporation $4,523.96 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612151
Principal investigator 1 Incyte Corporation $4,523.96 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612154
Principal investigator 1 Incyte Corporation $877.72 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612220
Principal investigator 1 Incyte Corporation $350.00 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612286
Principal investigator 1 Incyte Corporation $4,507.11 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612353
Principal investigator 1 Incyte Corporation $4,507.11 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612356
Principal investigator 1 Incyte Corporation $4,507.11 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612360
Principal investigator 1 Incyte Corporation $4,507.11 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612366
Principal investigator 1 Incyte Corporation $60.00 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612377
Principal investigator 1 Incyte Corporation $60.00 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612381
Principal investigator 1 Incyte Corporation $250.00 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612471
Principal investigator 1 Incyte Corporation $210.00 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612543
Principal investigator 1 Incyte Corporation $2,916.00 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612550
Principal investigator 1 Incyte Corporation $2,916.00 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612555
Principal investigator 1 Incyte Corporation $2,916.00 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612560
Principal investigator 1 Incyte Corporation $4,534.88 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612563
Principal investigator 1 Incyte Corporation $429.73 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612571
Principal investigator 1 Incyte Corporation $110.00 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612637
Principal investigator 1 Incyte Corporation $3,780.00 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612750
Principal investigator 1 Incyte Corporation $3,780.00 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612753
Principal investigator 1 Incyte Corporation $3,780.00 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612757
Principal investigator 1 Incyte Corporation $4,533.12 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612783
Principal investigator 1 Incyte Corporation $4,533.12 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612787
Principal investigator 1 Incyte Corporation $4,533.12 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612791
Principal investigator 1 Incyte Corporation $5,675.00 12/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612855
Principal investigator 1 BeOne Medicines Ltd. $12,349.07 12/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190336054
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $8,859.59 12/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220996850
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $81,860.85 12/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220996884
Principal investigator 1 Boehringer Ingelheim International GmbH $5,688.00 12/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704137
Principal investigator 1 Boehringer Ingelheim International GmbH $4,050.00 12/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704139
Principal investigator 1 Boehringer Ingelheim International GmbH $1,350.00 12/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704141
Principal investigator 1 Boehringer Ingelheim International GmbH $5,400.00 12/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704143
Principal investigator 1 Boehringer Ingelheim International GmbH $1,300.00 12/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704145
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $17,705.25 12/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804967
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $17,689.05 12/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804969
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $19,941.53 12/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805643
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,734.53 12/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805645
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,250.00 12/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
An open label trial of BI 765063 in combination with BI 754091 (ezabenlimab) alone or with BI 836880, chemotherapy, or cetuximab, in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) or hepatocellular carcinoma (HCC) No dispute reported 06/30/2026 1220805649
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,250.00 12/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
An open label trial of BI 765063 in combination with BI 754091 (ezabenlimab) alone or with BI 836880, chemotherapy, or cetuximab, in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) or hepatocellular carcinoma (HCC) No dispute reported 06/30/2026 1220805651
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,038.00 12/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
An open label trial of BI 765063 in combination with BI 754091 (ezabenlimab) alone or with BI 836880, chemotherapy, or cetuximab, in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) or hepatocellular carcinoma (HCC) No dispute reported 06/30/2026 1220805653
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,000.00 12/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
An open label trial of BI 765063 in combination with BI 754091 (ezabenlimab) alone or with BI 836880, chemotherapy, or cetuximab, in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) or hepatocellular carcinoma (HCC) No dispute reported 06/30/2026 1220805655
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,500.00 12/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
An open label trial of BI 765063 in combination with BI 754091 (ezabenlimab) alone or with BI 836880, chemotherapy, or cetuximab, in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) or hepatocellular carcinoma (HCC) No dispute reported 06/30/2026 1220805657
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,175.00 12/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805797
Principal investigator 1 Daiichi Sankyo Inc. $55.00 12/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389757
Principal investigator 1 Daiichi Sankyo Inc. $540.00 12/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389765
Principal investigator 1 Daiichi Sankyo Inc. $84.00 12/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389773
Principal investigator 1 Daiichi Sankyo Inc. $154.00 12/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389775
Principal investigator 1 Daiichi Sankyo Inc. $32.00 12/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389777
Principal investigator 1 Daiichi Sankyo Inc. $57.00 12/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389779
Principal investigator 1 Daiichi Sankyo Inc. $205.00 12/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389795
Principal investigator 1 Daiichi Sankyo Inc. $72.00 12/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389797
Principal investigator 1 Daiichi Sankyo Inc. $55.00 12/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389801
Principal investigator 1 Daiichi Sankyo Inc. $100.00 12/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389809
Principal investigator 1 Daiichi Sankyo Inc. $81.00 12/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389811
Principal investigator 1 Daiichi Sankyo Inc. $58.00 12/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389813
Principal investigator 1 Daiichi Sankyo Inc. $105.00 12/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389819
Principal investigator 1 Daiichi Sankyo Inc. $135.00 12/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389821
Principal investigator 1 Genentech, Inc. $4,691.40 12/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211682016
Principal investigator 1 Genentech, Inc. $4,421.80 12/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211682020
Principal investigator 1 Genentech, Inc. $20,098.32 12/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211682024
Principal investigator 1 Genentech, Inc. $5,911.37 12/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211682026
Principal investigator 1 Genentech, Inc. $20,028.00 12/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211682028
Principal investigator 1 Janssen Research & Development, LLC $20,560.00 12/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175413773
Principal investigator 1 BioNTech SE $34.00 12/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012767
Principal investigator 1 BioNTech SE $77.00 12/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012771
Principal investigator 1 BioNTech SE $214.00 12/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012773
Principal investigator 1 BioNTech SE $34.00 12/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012775
Principal investigator 1 BioNTech SE $154.00 12/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012805
Principal investigator 1 BioNTech SE $101.00 12/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012807
Principal investigator 1 BioNTech SE $77.00 12/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012809
Principal investigator 1 BioNTech SE $6,647.00 12/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013063
Principal investigator 1 Daiichi Sankyo Inc. $135.00 12/12/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389791
Principal investigator 1 Daiichi Sankyo Inc. $1,013.00 12/12/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389803
Principal investigator 1 Daiichi Sankyo Inc. $135.00 12/12/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389817
Principal investigator 1 Daiichi Sankyo Inc. $115.00 12/12/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389827
Principal investigator 1 Incyte Corporation $368.00 12/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240611505
Principal investigator 1 Incyte Corporation $700.00 12/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611538
Principal investigator 1 Incyte Corporation $440.00 12/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611743
Principal investigator 1 Incyte Corporation $480.00 12/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611975
Principal investigator 1 Incyte Corporation $840.00 12/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612112
Principal investigator 1 Incyte Corporation $1,400.00 12/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612124
Principal investigator 1 Incyte Corporation $750.00 12/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612129
Principal investigator 1 Incyte Corporation $1,000.00 12/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612373
Principal investigator 1 Incyte Corporation $600.00 12/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240612426
Principal investigator 1 Incyte Corporation $600.00 12/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240612431
Principal investigator 1 Incyte Corporation $600.00 12/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240612435
Principal investigator 1 Incyte Corporation $1,688.00 12/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612712
Principal investigator 1 Incyte Corporation $300.00 12/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240612741
Principal investigator 1 Incyte Corporation $300.00 12/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240612746
Principal investigator 1 BioNTech SE $675.00 12/11/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012693
Principal investigator 1 BioNTech SE $574.00 12/11/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012701
Principal investigator 1 BioNTech SE $135.00 12/11/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012867
Principal investigator 1 BioNTech SE $77.00 12/11/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012887
Principal investigator 1 BioNTech SE $2,835.00 12/11/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012891
Principal investigator 1 BioNTech SE $203.00 12/11/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012893
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $793.00 12/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805781
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,000.00 12/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805783
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $386.60 12/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805785
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,641.00 12/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805787
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,625.00 12/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805789
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,175.00 12/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805791
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,450.00 12/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805793
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,175.00 12/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805795
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $131,253.74 12/11/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184274376
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,391.35 12/11/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184274380
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,428.00 12/11/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184274382
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,121.55 12/11/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184274384
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $185.00 12/11/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184274386
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $296.45 12/11/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184274388
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $81.87 12/11/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184274390
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $23.11 12/11/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184274392
Principal investigator 1 ABBVIE INC. $456.50 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202529858
Principal investigator 1 ABBVIE INC. $489.23 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202529860
Principal investigator 1 ABBVIE INC. $367.07 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202529862
Principal investigator 1 ABBVIE INC. $587.40 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202529930
Principal investigator 1 ABBVIE INC. $603.76 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202529932
Principal investigator 1 BeOne Medicines Ltd. $260.00 12/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190329249
Principal investigator 1 BeOne Medicines Ltd. $118.00 12/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190329311
Principal investigator 1 BeOne Medicines Ltd. $2,600.00 12/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334493
Principal investigator 1 BeOne Medicines Ltd. $4,550.00 12/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334509
Principal investigator 1 BeOne Medicines Ltd. $52.00 12/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334533
Principal investigator 1 BeOne Medicines Ltd. $3,250.00 12/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334541
Principal investigator 1 BeOne Medicines Ltd. $1,300.00 12/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334545
Principal investigator 1 BeOne Medicines Ltd. $2,543.00 12/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334558
Principal investigator 1 BeOne Medicines Ltd. $260.00 12/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334610
Principal investigator 1 BeOne Medicines Ltd. $4,680.00 12/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334655
Principal investigator 1 BeOne Medicines Ltd. $192.00 12/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334659
Principal investigator 1 BeOne Medicines Ltd. $1,300.00 12/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334671
Principal investigator 1 BeOne Medicines Ltd. $260.00 12/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334703
Principal investigator 1 BeOne Medicines Ltd. $230.31 12/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334711
Principal investigator 1 BeOne Medicines Ltd. $195.00 12/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334723
Principal investigator 1 BeOne Medicines Ltd. $1,138.00 12/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334743
Principal investigator 1 BeOne Medicines Ltd. $234.70 12/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334759
Principal investigator 1 BeOne Medicines Ltd. $65.00 12/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334767
Principal investigator 1 BeOne Medicines Ltd. $650.00 12/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334779
Principal investigator 1 BeOne Medicines Ltd. $1,950.00 12/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334797
Principal investigator 1 BeOne Medicines Ltd. $1,950.00 12/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334809
Principal investigator 1 BeOne Medicines Ltd. $65.00 12/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334848
Principal investigator 1 BeOne Medicines Ltd. $94,320.00 12/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190337093
Principal investigator 1 BeOne Medicines Ltd. $241.00 12/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190341606
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,500.00 12/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804794
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,965.00 12/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805637
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,991.25 12/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805639
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,400.00 12/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805641
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,439.00 12/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805815
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,439.00 12/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805817
Principal investigator 1 Incyte Corporation $2,275.00 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240611432
Principal investigator 1 Incyte Corporation $2,275.00 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240611436
Principal investigator 1 Incyte Corporation $2,915.00 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240611775
Principal investigator 1 Incyte Corporation $2,915.00 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240611779
Principal investigator 1 Incyte Corporation $6,863.00 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240611795
Principal investigator 1 Incyte Corporation $6,863.00 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240611797
Principal investigator 1 Incyte Corporation $6,863.00 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240611800
Principal investigator 1 Incyte Corporation $6,863.00 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240611805
Principal investigator 1 Incyte Corporation $6,863.00 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240611809
Principal investigator 1 Incyte Corporation $4,830.00 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240611900
Principal investigator 1 Incyte Corporation $7,925.00 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240611946
Principal investigator 1 Incyte Corporation $7,925.00 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240611950
Principal investigator 1 Incyte Corporation $7,925.00 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240611953
Principal investigator 1 Incyte Corporation $7,011.00 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240612178
Principal investigator 1 Incyte Corporation $7,011.00 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240612182
Principal investigator 1 Incyte Corporation $7,011.00 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240612186
Principal investigator 1 Incyte Corporation $4,759.00 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240612223
Principal investigator 1 Incyte Corporation $4,759.00 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240612227
Principal investigator 1 Incyte Corporation $4,759.00 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240612231
Principal investigator 1 Incyte Corporation $2,072.00 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240612452
Principal investigator 1 Incyte Corporation $2,072.00 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240612456
Principal investigator 1 Incyte Corporation $2,072.00 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240612459
Principal investigator 1 Incyte Corporation $7,748.00 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240612720
Principal investigator 1 Incyte Corporation $7,748.00 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240612723
Principal investigator 1 Incyte Corporation $7,748.00 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240612727
Principal investigator 1 Incyte Corporation $7,748.00 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240612730
Principal investigator 1 Incyte Corporation $2,477.00 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240612828
Principal investigator 1 Incyte Corporation $2,477.00 12/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. No dispute reported 06/30/2026 1240612831
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $17,554.39 12/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220996886
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,500.00 12/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804792
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,758.00 12/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804955
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22,176.00 12/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804957
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,516.00 12/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804959
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,516.00 12/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804961
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,000.00 12/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804963
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,500.00 12/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804965
Principal investigator 1 Genentech, Inc. $250.00 12/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Optimization of the CRS Profile for Glofit+GemOx in R/R DLBCL No dispute reported 06/30/2026 1211681958
Principal investigator 1 Daiichi Sankyo Inc. $1,376.00 12/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389759
Principal investigator 1 Daiichi Sankyo Inc. $8,250.00 12/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389763
Principal investigator 1 Daiichi Sankyo Inc. $405.21 12/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389767
Principal investigator 1 Daiichi Sankyo Inc. $529.92 12/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389783
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,519.00 12/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220804819
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,519.00 12/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220804821
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,500.00 12/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220804823
Principal investigator 1 Incyte Corporation $18,250.30 12/05/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611714
Principal investigator 1 Incyte Corporation $600.00 12/05/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611963
Principal investigator 1 Janssen Research & Development, LLC $20,560.00 12/05/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175413916
Principal investigator 1 ABBVIE INC. $26,662.50 12/04/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202528020
Principal investigator 1 ABBVIE INC. $23,698.58 12/04/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202528422
Principal investigator 1 ABBVIE INC. $4,538.84 12/04/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202529146
Principal investigator 1 Janssen Research & Development, LLC $20,560.00 12/04/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175414018
Principal investigator 1 BioNTech SE $101.00 12/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012769
Principal investigator 1 BioNTech SE $176.00 12/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012783
Principal investigator 1 BioNTech SE $70.00 12/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012785
Principal investigator 1 BioNTech SE $109.00 12/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012787
Principal investigator 1 BioNTech SE $63.00 12/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012789
Principal investigator 1 BioNTech SE $101.00 12/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012791
Principal investigator 1 BioNTech SE $39.00 12/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012793
Principal investigator 1 BioNTech SE $69.00 12/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012795
Principal investigator 1 BioNTech SE $163.00 12/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012797
Principal investigator 1 BioNTech SE $84.00 12/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012799
Principal investigator 1 BioNTech SE $46.00 12/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012801
Principal investigator 1 BioNTech SE $405.00 12/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012803
Principal investigator 1 BioNTech SE $149.00 12/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013061
Principal investigator 1 BioNTech SE $5,166.00 12/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013067
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $14,515.85 12/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220996856
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 12/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577748
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 12/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577750
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704135
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220704199
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220704201
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $41,674.00 12/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804790
Principal investigator 1 Genentech, Inc. $56.80 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211682014
Principal investigator 1 Genentech, Inc. $1,099.98 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211682022
Principal investigator 1 Incyte Corporation $50.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611392
Principal investigator 1 Incyte Corporation $50.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611395
Principal investigator 1 Incyte Corporation $2,916.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611410
Principal investigator 1 Incyte Corporation $2,916.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611415
Principal investigator 1 Incyte Corporation $2,916.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611419
Principal investigator 1 Incyte Corporation $184.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611441
Principal investigator 1 Incyte Corporation $171.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611445
Principal investigator 1 Incyte Corporation $171.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611449
Principal investigator 1 Incyte Corporation $171.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611454
Principal investigator 1 Incyte Corporation $4,131.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611625
Principal investigator 1 Incyte Corporation $80.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611723
Principal investigator 1 Incyte Corporation $80.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611727
Principal investigator 1 Incyte Corporation $107.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611756
Principal investigator 1 Incyte Corporation $2,351.70 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611833
Principal investigator 1 Incyte Corporation $58.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611835
Principal investigator 1 Incyte Corporation $58.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611840
Principal investigator 1 Incyte Corporation $99.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611844
Principal investigator 1 Incyte Corporation $63.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611998
Principal investigator 1 Incyte Corporation $63.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612002
Principal investigator 1 Incyte Corporation $3,780.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612028
Principal investigator 1 Incyte Corporation $3,780.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612036
Principal investigator 1 Incyte Corporation $3,780.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612040
Principal investigator 1 Incyte Corporation $70.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612043
Principal investigator 1 Incyte Corporation $70.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612047
Principal investigator 1 Incyte Corporation $70.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612050
Principal investigator 1 Incyte Corporation $70.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612054
Principal investigator 1 Incyte Corporation $70.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612058
Principal investigator 1 Incyte Corporation $70.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612061
Principal investigator 1 Incyte Corporation $45.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612415
Principal investigator 1 Incyte Corporation $376.65 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612509
Principal investigator 1 Incyte Corporation $1,744.70 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612567
Principal investigator 1 Incyte Corporation $675.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612619
Principal investigator 1 Incyte Corporation $65.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612629
Principal investigator 1 Incyte Corporation $65.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612633
Principal investigator 1 Incyte Corporation $242.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612649
Principal investigator 1 Incyte Corporation $242.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612652
Principal investigator 1 Incyte Corporation $3,040.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612681
Principal investigator 1 Incyte Corporation $3,040.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612684
Principal investigator 1 Incyte Corporation $3,040.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612689
Principal investigator 1 Incyte Corporation $750.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612734
Principal investigator 1 Incyte Corporation $74.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612775
Principal investigator 1 Incyte Corporation $74.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612780
Principal investigator 1 Incyte Corporation $371.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612893
Principal investigator 1 Incyte Corporation $84.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612896
Principal investigator 1 Incyte Corporation $84.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612900
Principal investigator 1 Incyte Corporation $84.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612904
Principal investigator 1 Incyte Corporation $84.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612907
Principal investigator 1 Incyte Corporation $84.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612911
Principal investigator 1 Incyte Corporation $84.00 12/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612918
Principal investigator 1 PFIZER INC. $24,273.44 12/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228715131
Principal investigator 1 PFIZER INC. $2,000.00 12/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228715311
Principal investigator 1 PFIZER INC. $28,297.52 12/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228715413
Principal investigator 1 Boehringer Ingelheim International GmbH $133.41 11/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704449
Principal investigator 1 Boehringer Ingelheim International GmbH $133.41 11/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704451
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $81,860.85 11/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220996880
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $5,279.04 11/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220996882
Principal investigator 1 Incyte Corporation $70.00 11/28/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611371
Principal investigator 1 Incyte Corporation $70.00 11/28/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611375
Principal investigator 1 Incyte Corporation $70.00 11/28/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611379
Principal investigator 1 Incyte Corporation $123.00 11/28/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611423
Principal investigator 1 Incyte Corporation $80.00 11/28/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611531
Principal investigator 1 Incyte Corporation $50.00 11/28/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611535
Principal investigator 1 Incyte Corporation $162.00 11/28/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611709
Principal investigator 1 Incyte Corporation $58.00 11/28/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611760
Principal investigator 1 Incyte Corporation $65.00 11/28/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611763
Principal investigator 1 Incyte Corporation $63.00 11/28/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611959
Principal investigator 1 Incyte Corporation $84.00 11/28/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612272
Principal investigator 1 Incyte Corporation $84.00 11/28/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612276
Principal investigator 1 Incyte Corporation $242.00 11/28/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612797
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 11/28/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175413840
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $16,097.00 11/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804953
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $43,050.58 11/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
An open label trial of BI 765063 in combination with BI 754091 (ezabenlimab) alone or with BI 836880, chemotherapy, or cetuximab, in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) or hepatocellular carcinoma (HCC) No dispute reported 06/30/2026 1220805647
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $26,405.00 11/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805813
Principal investigator 1 Incyte Corporation $123.42 11/26/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612547
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,460.25 11/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805811
Principal investigator 1 Genentech, Inc. $125,191.00 11/25/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Optimization of the CRS Profile for Glofit+GemOx in R/R DLBCL No dispute reported 06/30/2026 1211681956
Principal investigator 1 BioNTech SE $77.00 11/24/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012777
Principal investigator 1 BioNTech SE $50.00 11/24/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012779
Principal investigator 1 BioNTech SE $101.00 11/24/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012781
Principal investigator 1 BioNTech SE $5,166.45 11/24/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013065
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $756.97 11/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805777
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $296.60 11/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805779
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $498.35 11/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805809
Principal investigator 1 Janssen Research & Development, LLC $289.67 11/24/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175413723
Principal investigator 1 Janssen Research & Development, LLC $277.55 11/24/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175413737
Principal investigator 1 Janssen Research & Development, LLC $350.00 11/24/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175413768
Principal investigator 1 Janssen Research & Development, LLC $350.00 11/24/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175413851
Principal investigator 1 Janssen Research & Development, LLC $335.82 11/24/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175413858
Principal investigator 1 Janssen Research & Development, LLC $350.00 11/24/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175413866
Principal investigator 1 Janssen Research & Development, LLC $350.00 11/24/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175414024
Principal investigator 1 Boehringer Ingelheim International GmbH $790.00 11/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704103
Principal investigator 1 Boehringer Ingelheim International GmbH $3,510.00 11/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704107
Principal investigator 1 Boehringer Ingelheim International GmbH $6,210.00 11/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704109
Principal investigator 1 Boehringer Ingelheim International GmbH $380.00 11/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704111
Principal investigator 1 Boehringer Ingelheim International GmbH $990.00 11/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704113
Principal investigator 1 Boehringer Ingelheim International GmbH $725.00 11/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704115
Principal investigator 1 Boehringer Ingelheim International GmbH $5,777.00 11/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704117
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,429.10 11/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805799
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,429.10 11/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805801
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,382.10 11/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805803
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,449.10 11/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805805
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,178.25 11/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805807
Principal investigator 1 Daiichi Sankyo Inc. $72.00 11/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388451
Principal investigator 1 Daiichi Sankyo Inc. $205.00 11/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388463
Principal investigator 1 Daiichi Sankyo Inc. $135.00 11/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388469
Principal investigator 1 Daiichi Sankyo Inc. $52.48 11/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388479
Principal investigator 1 ABBVIE INC. $14,735.00 11/20/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202524982
Principal investigator 1 ABBVIE INC. $421.97 11/20/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202524984
Principal investigator 1 BeOne Medicines Ltd. $2,860.00 11/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334715
Principal investigator 1 BeOne Medicines Ltd. $4,364.00 11/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334819
Principal investigator 1 BeOne Medicines Ltd. $4,364.00 11/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334851
Principal investigator 1 BeOne Medicines Ltd. $3,549.00 11/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190341610
Principal investigator 1 Janssen Research & Development, LLC $49,869.00 11/19/2025 Non-covered Recipient Entity
Beverly Hills Cancer Ctr
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175167450
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22,700.00 11/17/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805775
Principal investigator 1 Incyte Corporation $210.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611383
Principal investigator 1 Incyte Corporation $2,150.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611389
Principal investigator 1 Incyte Corporation $1,250.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611543
Principal investigator 1 Incyte Corporation $2,200.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611566
Principal investigator 1 Incyte Corporation $3,000.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611613
Principal investigator 1 Incyte Corporation $11,350.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611640
Principal investigator 1 Incyte Corporation $17,500.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611770
Principal investigator 1 Incyte Corporation $110.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612264
Principal investigator 1 Incyte Corporation $60.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612317
Principal investigator 1 Incyte Corporation $60.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612322
Principal investigator 1 Incyte Corporation $3,780.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612326
Principal investigator 1 Incyte Corporation $3,780.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612330
Principal investigator 1 Incyte Corporation $3,780.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612334
Principal investigator 1 Incyte Corporation $3,780.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612338
Principal investigator 1 Incyte Corporation $3,780.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612343
Principal investigator 1 Incyte Corporation $1.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612391
Principal investigator 1 Incyte Corporation $175.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612438
Principal investigator 1 Incyte Corporation $2,500.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612443
Principal investigator 1 Incyte Corporation $2,500.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612447
Principal investigator 1 Incyte Corporation $2,916.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612489
Principal investigator 1 Incyte Corporation $2,916.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612493
Principal investigator 1 Incyte Corporation $2,916.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612498
Principal investigator 1 Incyte Corporation $2,916.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612502
Principal investigator 1 Incyte Corporation $2,916.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612505
Principal investigator 1 Incyte Corporation $250.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612771
Principal investigator 1 Incyte Corporation $3,040.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612801
Principal investigator 1 Incyte Corporation $3,040.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612805
Principal investigator 1 Incyte Corporation $3,040.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612811
Principal investigator 1 Incyte Corporation $3,040.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612814
Principal investigator 1 Incyte Corporation $3,040.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612816
Principal investigator 1 Incyte Corporation $5,675.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612820
Principal investigator 1 Incyte Corporation $5,675.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612824
Principal investigator 1 Incyte Corporation $350.00 11/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612844
Principal investigator 1 Boehringer Ingelheim International GmbH $8,500.00 11/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704119
Principal investigator 1 Boehringer Ingelheim International GmbH $1,929.00 11/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704125
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,253.55 11/14/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184261151
Principal investigator 1 Janssen Research & Development, LLC $700.00 11/13/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175413718
Principal investigator 1 Incyte Corporation $6,759.00 11/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611362
Principal investigator 1 Incyte Corporation $6,759.00 11/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611367
Principal investigator 1 Incyte Corporation $3,487.00 11/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611458
Principal investigator 1 Incyte Corporation $1,845.00 11/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611706
Principal investigator 1 Incyte Corporation $2,978.00 11/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611752
Principal investigator 1 Incyte Corporation $6,278.00 11/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612008
Principal investigator 1 Incyte Corporation $93.50 11/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612089
Principal investigator 1 Incyte Corporation $3,687.00 11/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612092
Principal investigator 1 Incyte Corporation $2,681.00 11/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612298
Principal investigator 1 Incyte Corporation $2,681.00 11/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612303
Principal investigator 1 Incyte Corporation $2,896.00 11/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612474
Principal investigator 1 Incyte Corporation $2,896.00 11/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612478
Principal investigator 1 Incyte Corporation $1,894.00 11/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612623
Principal investigator 1 Incyte Corporation $2,932.00 11/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612645
Principal investigator 1 Incyte Corporation $9,920.00 11/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612656
Principal investigator 1 Incyte Corporation $5,349.00 11/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612716
Principal investigator 1 Incyte Corporation $2,090.00 11/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612764
Principal investigator 1 Incyte Corporation $3,051.00 11/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612768
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $416.93 11/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805631
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $271.91 11/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805633
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $265.56 11/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805635
Principal investigator 1 Incyte Corporation $413.80 11/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240612403
Principal investigator 1 Incyte Corporation $726.00 11/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240612761
Principal investigator 1 Janssen Research & Development, LLC $11,824.00 11/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175413742
Principal investigator 1 BeOne Medicines Ltd. $3,050.00 11/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190341618
Principal investigator 1 BioNTech SE $211.00 11/07/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012695
Principal investigator 1 BioNTech SE $625.00 11/07/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012699
Principal investigator 1 BioNTech SE $135.00 11/07/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012871
Principal investigator 1 BioNTech SE $135.00 11/07/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012873
Principal investigator 1 BioNTech SE $1,333.00 11/07/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012875
Principal investigator 1 BioNTech SE $115.00 11/07/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012879
Principal investigator 1 BioNTech SE $3,038.00 11/07/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012885
Principal investigator 1 BioNTech SE $675.00 11/07/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012899
Principal investigator 1 Incyte Corporation $3,040.00 11/07/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240611569
Principal investigator 1 Incyte Corporation $3,780.00 11/07/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612482
Principal investigator 1 Incyte Corporation $2,916.00 11/07/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors No dispute reported 06/30/2026 1240612486
Principal investigator 1 Janssen Research & Development, LLC $15,126.00 11/07/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175413760
Principal investigator 1 Janssen Research & Development, LLC $8,031.00 11/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175414030
Principal investigator 1 ABBVIE INC. $32,887.35 11/05/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202522739
Principal investigator 1 ABBVIE INC. $3,866.94 11/05/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202522785
Principal investigator 1 ABBVIE INC. $11,586.40 11/05/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202523141
Principal investigator 1 Incyte Corporation $2,916.00 11/05/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611669
Principal investigator 1 Incyte Corporation $2,916.00 11/05/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611675
Principal investigator 1 Incyte Corporation $2,916.00 11/05/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611679
Principal investigator 1 Incyte Corporation $2,916.00 11/05/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611683
Principal investigator 1 Incyte Corporation $3,780.00 11/05/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611848
Principal investigator 1 Incyte Corporation $3,780.00 11/05/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611851
Principal investigator 1 Incyte Corporation $3,780.00 11/05/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611855
Principal investigator 1 Incyte Corporation $3,780.00 11/05/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611859
Principal investigator 1 Incyte Corporation $3,040.00 11/05/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612236
Principal investigator 1 Incyte Corporation $3,040.00 11/05/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612240
Principal investigator 1 Incyte Corporation $3,040.00 11/05/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612244
Principal investigator 1 Incyte Corporation $3,040.00 11/05/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612249
Principal investigator 1 Incyte Corporation $5,675.00 11/05/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612641
Principal investigator 1 BioNTech SE $1,823.00 11/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012811
Principal investigator 1 Boehringer Ingelheim International GmbH $145.00 11/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704105
Principal investigator 1 Boehringer Ingelheim International GmbH $7,439.00 11/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704121
Principal investigator 1 Boehringer Ingelheim International GmbH $8,201.00 11/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704123
Principal investigator 1 Boehringer Ingelheim International GmbH $47.00 11/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704127
Principal investigator 1 Boehringer Ingelheim International GmbH $61.00 11/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704129
Principal investigator 1 Boehringer Ingelheim International GmbH $101.00 11/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704131
Principal investigator 1 Boehringer Ingelheim International GmbH $101.00 11/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704133
Principal investigator 1 Incyte Corporation $2,916.00 11/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611523
Principal investigator 1 Incyte Corporation $2,916.00 11/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611527
Principal investigator 1 Incyte Corporation $3,780.00 11/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611585
Principal investigator 1 Incyte Corporation $3,780.00 11/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611589
Principal investigator 1 Incyte Corporation $3,040.00 11/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611981
Principal investigator 1 Incyte Corporation $3,040.00 11/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611985
Principal investigator 1 Incyte Corporation $5,675.00 11/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612847
Principal investigator 1 Incyte Corporation $5,675.00 11/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612851
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 11/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577744
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 11/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577746
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704101
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220704195
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220704197
Principal investigator 1 Boehringer Ingelheim International GmbH $405.00 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704309
Principal investigator 1 Boehringer Ingelheim International GmbH $1,166.75 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704311
Principal investigator 1 Boehringer Ingelheim International GmbH $675.00 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704313
Principal investigator 1 Boehringer Ingelheim International GmbH $835.65 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704315
Principal investigator 1 Boehringer Ingelheim International GmbH $94.50 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704317
Principal investigator 1 Boehringer Ingelheim International GmbH $1,197.45 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704319
Principal investigator 1 Boehringer Ingelheim International GmbH $285.00 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704321
Principal investigator 1 Boehringer Ingelheim International GmbH $436.05 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704323
Principal investigator 1 Boehringer Ingelheim International GmbH $143.10 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704325
Principal investigator 1 Boehringer Ingelheim International GmbH $121.50 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704327
Principal investigator 1 Boehringer Ingelheim International GmbH $675.00 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704329
Principal investigator 1 Boehringer Ingelheim International GmbH $636.03 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704331
Principal investigator 1 Boehringer Ingelheim International GmbH $153.90 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704333
Principal investigator 1 Boehringer Ingelheim International GmbH $529.20 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704335
Principal investigator 1 Boehringer Ingelheim International GmbH $209.25 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704337
Principal investigator 1 Boehringer Ingelheim International GmbH $1,518.75 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704339
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704341
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704343
Principal investigator 1 Boehringer Ingelheim International GmbH $978.75 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704345
Principal investigator 1 Boehringer Ingelheim International GmbH $7,947.20 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704347
Principal investigator 1 Boehringer Ingelheim International GmbH $3,216.28 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704349
Principal investigator 1 Boehringer Ingelheim International GmbH $2,025.00 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704351
Principal investigator 1 Boehringer Ingelheim International GmbH $2,594.70 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704353
Principal investigator 1 Boehringer Ingelheim International GmbH $6,362.31 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704355
Principal investigator 1 Boehringer Ingelheim International GmbH $2,145.15 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704357
Principal investigator 1 Boehringer Ingelheim International GmbH $6,432.56 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704359
Principal investigator 1 Boehringer Ingelheim International GmbH $7,500.00 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704361
Principal investigator 1 Boehringer Ingelheim International GmbH $9,750.00 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704363
Principal investigator 1 Boehringer Ingelheim International GmbH $3,037.50 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704365
Principal investigator 1 Boehringer Ingelheim International GmbH $9,450.00 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704367
Principal investigator 1 Boehringer Ingelheim International GmbH $133.41 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704441
Principal investigator 1 Boehringer Ingelheim International GmbH $133.41 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704443
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $306,978.20 10/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220996756
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $16,674.00 10/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804788
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $316.22 10/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805343
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $426.11 10/29/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804780
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $423.75 10/29/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804782
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $409.75 10/29/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804784
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $374.51 10/29/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804786
Principal investigator 1 Incyte Corporation $5,675.00 10/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611592
Principal investigator 1 Incyte Corporation $5,675.00 10/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611596
Principal investigator 1 Incyte Corporation $5,675.00 10/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611599
Principal investigator 1 Incyte Corporation $5,675.00 10/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611604
Principal investigator 1 Incyte Corporation $5,675.00 10/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611609
Principal investigator 1 Incyte Corporation $2,916.00 10/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611813
Principal investigator 1 Incyte Corporation $2,916.00 10/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611817
Principal investigator 1 Incyte Corporation $2,916.00 10/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611821
Principal investigator 1 Incyte Corporation $2,916.00 10/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611825
Principal investigator 1 Incyte Corporation $2,916.00 10/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611829
Principal investigator 1 Incyte Corporation $4,131.00 10/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612011
Principal investigator 1 Incyte Corporation $3,780.00 10/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612065
Principal investigator 1 Incyte Corporation $3,780.00 10/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612069
Principal investigator 1 Incyte Corporation $3,780.00 10/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612073
Principal investigator 1 Incyte Corporation $3,780.00 10/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612077
Principal investigator 1 Incyte Corporation $3,780.00 10/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612081
Principal investigator 1 Incyte Corporation $2,068.00 10/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612349
Principal investigator 1 Incyte Corporation $3,040.00 10/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612592
Principal investigator 1 Incyte Corporation $3,040.00 10/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612600
Principal investigator 1 Incyte Corporation $3,040.00 10/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612603
Principal investigator 1 Incyte Corporation $3,040.00 10/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612607
Principal investigator 1 Incyte Corporation $3,040.00 10/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612611
Principal investigator 1 BeOne Medicines Ltd. $1,555.66 10/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190336051
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $158.11 10/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805341
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $350.27 10/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805629
Principal investigator 1 Daiichi Sankyo Inc. $2,801.00 10/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388477
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 10/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389781
Principal investigator 1 Daiichi Sankyo Inc. $379.00 10/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389787
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 10/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389793
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 10/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389799
Principal investigator 1 Incyte Corporation $600.00 10/24/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611633
Principal investigator 1 Incyte Corporation $142.95 10/24/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612467
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,672.00 10/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804951
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22,299.00 10/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805339
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,140.80 10/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805627
Principal investigator 1 ABBVIE INC. $726.00 10/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202518111
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,578.00 10/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805337
Principal investigator 1 BeOne Medicines Ltd. $65.00 10/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190329285
Principal investigator 1 BeOne Medicines Ltd. $65.00 10/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190329303
Principal investigator 1 BeOne Medicines Ltd. $98.00 10/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190329323
Principal investigator 1 BeOne Medicines Ltd. $1,025.00 10/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334502
Principal investigator 1 BeOne Medicines Ltd. $260.00 10/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334550
Principal investigator 1 BeOne Medicines Ltd. $52.00 10/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334606
Principal investigator 1 BeOne Medicines Ltd. $52.00 10/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334631
Principal investigator 1 BeOne Medicines Ltd. $130.00 10/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334663
Principal investigator 1 BeOne Medicines Ltd. $2,893.00 10/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334771
Principal investigator 1 BeOne Medicines Ltd. $325.00 10/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334775
Recipient Regeneron Pharmaceuticals, Inc. $419.92 10/19/2025 Covered Recipient Physician A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184115627
Recipient Regeneron Pharmaceuticals, Inc. $419.92 10/19/2025 Covered Recipient Physician A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184115629
Principal investigator 1 Genentech, Inc. $46,781.00 10/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211682012
Principal investigator 1 BioNTech SE $135.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012703
Principal investigator 1 BioNTech SE $135.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012707
Principal investigator 1 BioNTech SE $135.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012709
Principal investigator 1 BioNTech SE $675.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012711
Principal investigator 1 BioNTech SE $379.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012713
Principal investigator 1 BioNTech SE $135.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012715
Principal investigator 1 BioNTech SE $1,772.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012717
Principal investigator 1 BioNTech SE $1,147.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012719
Principal investigator 1 BioNTech SE $2,200.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012721
Principal investigator 1 BioNTech SE $203.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012723
Principal investigator 1 BioNTech SE $115.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012725
Principal investigator 1 BioNTech SE $115.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012727
Principal investigator 1 BioNTech SE $313.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012731
Principal investigator 1 BioNTech SE $77.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012733
Principal investigator 1 BioNTech SE $6,485.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012735
Principal investigator 1 BioNTech SE $201.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012737
Principal investigator 1 BioNTech SE $177.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012741
Principal investigator 1 BioNTech SE $101.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012743
Principal investigator 1 BioNTech SE $101.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012745
Principal investigator 1 Incyte Corporation $3,487.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611481
Principal investigator 1 Incyte Corporation $3,487.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611485
Principal investigator 1 Incyte Corporation $2,090.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611488
Principal investigator 1 Incyte Corporation $2,090.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611493
Principal investigator 1 Incyte Corporation $2,090.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611497
Principal investigator 1 Incyte Corporation $1,845.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611550
Principal investigator 1 Incyte Corporation $1,845.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611554
Principal investigator 1 Incyte Corporation $1,845.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611558
Principal investigator 1 Incyte Corporation $3,687.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611786
Principal investigator 1 Incyte Corporation $3,687.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611790
Principal investigator 1 Incyte Corporation $3,051.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611863
Principal investigator 1 Incyte Corporation $3,051.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611867
Principal investigator 1 Incyte Corporation $3,051.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611870
Principal investigator 1 Incyte Corporation $2,807.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611889
Principal investigator 1 Incyte Corporation $2,807.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611893
Principal investigator 1 Incyte Corporation $2,807.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611896
Principal investigator 1 Incyte Corporation $2,896.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611923
Principal investigator 1 Incyte Corporation $2,896.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611927
Principal investigator 1 Incyte Corporation $6,278.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612159
Principal investigator 1 Incyte Corporation $6,278.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612163
Principal investigator 1 Incyte Corporation $6,278.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612166
Principal investigator 1 Incyte Corporation $4,242.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612170
Principal investigator 1 Incyte Corporation $4,242.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612174
Principal investigator 1 Incyte Corporation $2,485.30 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612189
Principal investigator 1 Incyte Corporation $9,920.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612194
Principal investigator 1 Incyte Corporation $9,920.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612197
Principal investigator 1 Incyte Corporation $9,920.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612201
Principal investigator 1 Incyte Corporation $9,920.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612207
Principal investigator 1 Incyte Corporation $1,894.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612253
Principal investigator 1 Incyte Corporation $1,894.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612257
Principal investigator 1 Incyte Corporation $1,894.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612261
Principal investigator 1 Incyte Corporation $2,932.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612664
Principal investigator 1 Incyte Corporation $2,932.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612669
Principal investigator 1 Incyte Corporation $2,681.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612672
Principal investigator 1 Incyte Corporation $2,681.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612677
Principal investigator 1 Incyte Corporation $5,349.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612865
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,872.62 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184250537
Principal investigator 1 SEAGEN INC. $25,341.00 10/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 2 MULTICOHORT OPENLABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48ADC ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH LOCALLYADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 No dispute reported 06/30/2026 1228814296
Principal investigator 1 BeOne Medicines Ltd. $47,160.00 10/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190336802
Principal investigator 1 Daiichi Sankyo Inc. $40.88 10/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388715
Principal investigator 1 Incyte Corporation $122.00 10/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611519
Principal investigator 1 Incyte Corporation $1,710.45 10/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611620
Principal investigator 1 Incyte Corporation $675.00 10/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611636
Principal investigator 1 Incyte Corporation $300.00 10/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611649
Principal investigator 1 Incyte Corporation $300.00 10/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611653
Principal investigator 1 Incyte Corporation $300.00 10/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611656
Principal investigator 1 Incyte Corporation $300.00 10/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611662
Principal investigator 1 Incyte Corporation $889.34 10/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611687
Principal investigator 1 Incyte Corporation $5,305.00 10/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611749
Principal investigator 1 Incyte Corporation $900.00 10/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611783
Principal investigator 1 Incyte Corporation $589.34 10/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611903
Principal investigator 1 Incyte Corporation $589.34 10/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611907
Principal investigator 1 Incyte Corporation $895.15 10/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611941
Principal investigator 1 Incyte Corporation $745.47 10/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612019
Principal investigator 1 Incyte Corporation $234.00 10/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240612116
Principal investigator 1 Incyte Corporation $234.00 10/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240612119
Principal investigator 1 Incyte Corporation $61.00 10/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240612209
Principal investigator 1 Incyte Corporation $1,189.34 10/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612268
Principal investigator 1 Incyte Corporation $740.00 10/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240612281
Principal investigator 1 Incyte Corporation $4,836.00 10/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240612289
Principal investigator 1 Incyte Corporation $581.20 10/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612291
Principal investigator 1 Incyte Corporation $866.10 10/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612526
Principal investigator 1 Incyte Corporation $600.00 10/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612535
Principal investigator 1 Incyte Corporation $1,250.00 10/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240612573
Principal investigator 1 Incyte Corporation $520.00 10/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240612576
Principal investigator 1 Incyte Corporation $81.42 10/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612705
Principal investigator 1 Incyte Corporation $6,570.45 10/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240612737
Principal investigator 1 Incyte Corporation $277.71 10/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612835
Principal investigator 1 ABBVIE INC. $786.49 10/14/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202516637
Principal investigator 1 ABBVIE INC. $1,663.00 10/14/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202516639
Principal investigator 1 ABBVIE INC. $14,621.85 10/14/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202516641
Principal investigator 1 ABBVIE INC. $821.00 10/14/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202516659
Principal investigator 1 ABBVIE INC. $3,529.00 10/14/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202516671
Principal investigator 1 ABBVIE INC. $1,345.00 10/14/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202516673
Principal investigator 1 ABBVIE INC. $1,586.00 10/14/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202516679
Principal investigator 1 ABBVIE INC. $884.00 10/14/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202516685
Principal investigator 1 ABBVIE INC. $1,779.00 10/14/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202516687
Principal investigator 1 ABBVIE INC. $2,518.00 10/14/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202516689
Principal investigator 1 ABBVIE INC. $1,525.00 10/14/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202516697
Principal investigator 1 ABBVIE INC. $1,410.00 10/14/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202516699
Principal investigator 1 ABBVIE INC. $4,773.00 10/14/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202516701
Principal investigator 1 ABBVIE INC. $1,812.00 10/14/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202516703
Principal investigator 1 ABBVIE INC. $2,440.00 10/14/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202516705
Principal investigator 1 BeOne Medicines Ltd. $15,927.12 10/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190336060
Principal investigator 1 BeOne Medicines Ltd. $16,587.12 10/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190336068
Principal investigator 1 Janssen Research & Development, LLC $20,560.00 10/13/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175413785
Principal investigator 1 Janssen Research & Development, LLC $20,560.00 10/13/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175414011
Principal investigator 1 Daiichi Sankyo Inc. $317.20 10/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388405
Principal investigator 1 Incyte Corporation $923.40 10/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612411
Principal investigator 1 ABBVIE INC. $4,288.00 10/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202514261
Principal investigator 1 ABBVIE INC. $3,149.00 10/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202514263
Principal investigator 1 ABBVIE INC. $16,746.75 10/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202514707
Principal investigator 1 ABBVIE INC. $2,924.00 10/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202514845
Principal investigator 1 ABBVIE INC. $3,023.00 10/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202514847
Principal investigator 1 ABBVIE INC. $5,029.00 10/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202514849
Principal investigator 1 ABBVIE INC. $30,475.00 10/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan No dispute reported 06/30/2026 1202515039
Principal investigator 1 ABBVIE INC. $917.00 10/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202515043
Principal investigator 1 ABBVIE INC. $1,190.00 10/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202515205
Principal investigator 1 ABBVIE INC. $5,887.00 10/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202515207
Principal investigator 1 ABBVIE INC. $1,485.47 10/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202515209
Principal investigator 1 ABBVIE INC. $2,603.00 10/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202515211
Principal investigator 1 ABBVIE INC. $4,252.50 10/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202515385
Principal investigator 1 ABBVIE INC. $25,180.88 10/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-4) No dispute reported 06/30/2026 1202515387
Principal investigator 1 ABBVIE INC. $3,771.00 10/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202515613
Principal investigator 1 ABBVIE INC. $2,317.28 10/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202516457
Principal investigator 1 BioNTech SE $21,089.00 10/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012729
Principal investigator 1 BioNTech SE $129.00 10/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012739
Principal investigator 1 ABBVIE INC. $1,624.05 10/08/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202513535
Principal investigator 1 ABBVIE INC. $4,386.00 10/08/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202513547
Principal investigator 1 ABBVIE INC. $14,621.85 10/08/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202513553
Principal investigator 1 ABBVIE INC. $4,658.00 10/08/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202513555
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,150.00 10/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805345
Principal investigator 1 Daiichi Sankyo Inc. $379.00 10/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389761
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 10/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389789
Principal investigator 1 Daiichi Sankyo Inc. $2,801.00 10/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389805
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 10/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389807
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 10/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389825
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,854.30 10/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805313
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,903.55 10/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805315
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,196.55 10/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805317
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,835.00 10/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805319
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,989.00 10/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805321
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $675.00 10/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805323
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,914.00 10/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805325
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $675.00 10/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805327
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,828.00 10/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805329
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,117.55 10/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805331
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,854.30 10/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805333
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,253.00 10/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805335
Principal investigator 1 Janssen Research & Development, LLC $9,758.00 10/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175413779
Principal investigator 1 BioNTech SE $21,189.00 10/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012881
Principal investigator 1 BioNTech SE $21,089.00 10/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012883
Principal investigator 1 BioNTech SE $258.00 10/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012895
Principal investigator 1 BioNTech SE $258.00 10/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327 No dispute reported 06/30/2026 1249012897
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $25,940.00 10/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805773
Principal investigator 1 Genentech, Inc. $116,719.75 10/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211681980
Principal investigator 1 Incyte Corporation $2,200.00 10/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611989
Principal investigator 1 Incyte Corporation $17,500.00 10/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612023
Principal investigator 1 Incyte Corporation $1,250.00 10/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612085
Principal investigator 1 Incyte Corporation $2,500.00 10/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612213
Principal investigator 1 Incyte Corporation $2,500.00 10/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612216
Principal investigator 1 Incyte Corporation $3,000.00 10/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612660
Principal investigator 1 Incyte Corporation $2,150.00 10/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612700
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $71,527.56 10/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184244569
Principal investigator 1 ABBVIE INC. $364.50 10/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202513073
Principal investigator 1 ABBVIE INC. $364.50 10/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202513075
Principal investigator 1 ABBVIE INC. $364.50 10/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202513087
Principal investigator 1 ABBVIE INC. $364.50 10/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202513107
Principal investigator 1 ABBVIE INC. $364.50 10/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202513109
Principal investigator 1 ABBVIE INC. $364.50 10/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202513111
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $491.40 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804768
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $885.70 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804770
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $414.45 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804772
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $356.40 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804774
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $337.50 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804776
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,248.50 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804778
Principal investigator 1 Daiichi Sankyo Inc. $6,727.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388397
Principal investigator 1 Daiichi Sankyo Inc. $103.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388399
Principal investigator 1 Daiichi Sankyo Inc. $405.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388401
Principal investigator 1 Daiichi Sankyo Inc. $1,046.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388403
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388407
Principal investigator 1 Daiichi Sankyo Inc. $675.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388409
Principal investigator 1 Daiichi Sankyo Inc. $2,250.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388411
Principal investigator 1 Daiichi Sankyo Inc. $675.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388415
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388417
Principal investigator 1 Daiichi Sankyo Inc. $2,801.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388419
Principal investigator 1 Daiichi Sankyo Inc. $42.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388421
Principal investigator 1 Daiichi Sankyo Inc. $6,818.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388423
Principal investigator 1 Daiichi Sankyo Inc. $80.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388425
Principal investigator 1 Daiichi Sankyo Inc. $4,050.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388427
Principal investigator 1 Daiichi Sankyo Inc. $1,083.99 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388429
Principal investigator 1 Daiichi Sankyo Inc. $185.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388433
Principal investigator 1 Daiichi Sankyo Inc. $2,668.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388437
Principal investigator 1 Daiichi Sankyo Inc. $105.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388439
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388441
Principal investigator 1 Daiichi Sankyo Inc. $1,920.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388443
Principal investigator 1 Daiichi Sankyo Inc. $205.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388445
Principal investigator 1 Daiichi Sankyo Inc. $78.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388447
Principal investigator 1 Daiichi Sankyo Inc. $641.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388449
Principal investigator 1 Daiichi Sankyo Inc. $743.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388455
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388457
Principal investigator 1 Daiichi Sankyo Inc. $135.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388461
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388465
Principal investigator 1 Daiichi Sankyo Inc. $58.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388467
Principal investigator 1 Daiichi Sankyo Inc. $2,000.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388471
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388473
Principal investigator 1 Daiichi Sankyo Inc. $85.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388475
Principal investigator 1 Daiichi Sankyo Inc. $84.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388485
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388487
Principal investigator 1 Daiichi Sankyo Inc. $1,750.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388489
Principal investigator 1 Daiichi Sankyo Inc. $72.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388491
Principal investigator 1 Daiichi Sankyo Inc. $113.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388495
Principal investigator 1 Daiichi Sankyo Inc. $50.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388497
Principal investigator 1 Daiichi Sankyo Inc. $115.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388645
Principal investigator 1 Daiichi Sankyo Inc. $236.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388647
Principal investigator 1 Daiichi Sankyo Inc. $69.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388649
Principal investigator 1 Daiichi Sankyo Inc. $135.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388651
Principal investigator 1 Daiichi Sankyo Inc. $69.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388653
Principal investigator 1 Daiichi Sankyo Inc. $113.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388655
Principal investigator 1 Daiichi Sankyo Inc. $270.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388657
Principal investigator 1 Daiichi Sankyo Inc. $135.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388659
Principal investigator 1 Daiichi Sankyo Inc. $105.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388661
Principal investigator 1 Daiichi Sankyo Inc. $55.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388663
Principal investigator 1 Daiichi Sankyo Inc. $574.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388665
Principal investigator 1 Daiichi Sankyo Inc. $58.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388667
Principal investigator 1 Daiichi Sankyo Inc. $135.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388669
Principal investigator 1 Daiichi Sankyo Inc. $42.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388671
Principal investigator 1 Daiichi Sankyo Inc. $135.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388673
Principal investigator 1 Daiichi Sankyo Inc. $69.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388675
Principal investigator 1 Daiichi Sankyo Inc. $135.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388677
Principal investigator 1 Daiichi Sankyo Inc. $198.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388679
Principal investigator 1 Daiichi Sankyo Inc. $115.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388681
Principal investigator 1 Daiichi Sankyo Inc. $135.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388683
Principal investigator 1 Daiichi Sankyo Inc. $42.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388685
Principal investigator 1 Daiichi Sankyo Inc. $84.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388687
Principal investigator 1 Daiichi Sankyo Inc. $205.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388689
Principal investigator 1 Daiichi Sankyo Inc. $69.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388691
Principal investigator 1 Daiichi Sankyo Inc. $169.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388693
Principal investigator 1 Daiichi Sankyo Inc. $42.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388695
Principal investigator 1 Daiichi Sankyo Inc. $135.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388697
Principal investigator 1 Daiichi Sankyo Inc. $50.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388699
Principal investigator 1 Daiichi Sankyo Inc. $405.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388701
Principal investigator 1 Daiichi Sankyo Inc. $185.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388703
Principal investigator 1 Daiichi Sankyo Inc. $108.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388705
Principal investigator 1 Daiichi Sankyo Inc. $103.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388707
Principal investigator 1 Daiichi Sankyo Inc. $135.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388709
Principal investigator 1 Daiichi Sankyo Inc. $135.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388711
Principal investigator 1 Daiichi Sankyo Inc. $203.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388713
Principal investigator 1 Daiichi Sankyo Inc. $263.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388717
Principal investigator 1 Daiichi Sankyo Inc. $85.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388719
Principal investigator 1 Daiichi Sankyo Inc. $80.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388721
Principal investigator 1 Daiichi Sankyo Inc. $72.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388723
Principal investigator 1 Daiichi Sankyo Inc. $810.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388725
Principal investigator 1 Daiichi Sankyo Inc. $100.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388727
Principal investigator 1 Daiichi Sankyo Inc. $506.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388729
Principal investigator 1 Daiichi Sankyo Inc. $135.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388731
Principal investigator 1 Daiichi Sankyo Inc. $135.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388733
Principal investigator 1 Daiichi Sankyo Inc. $135.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388735
Principal investigator 1 Daiichi Sankyo Inc. $58.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388737
Principal investigator 1 Daiichi Sankyo Inc. $143.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388739
Principal investigator 1 Daiichi Sankyo Inc. $115.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388741
Principal investigator 1 Daiichi Sankyo Inc. $42.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388743
Principal investigator 1 Daiichi Sankyo Inc. $57.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388745
Principal investigator 1 Daiichi Sankyo Inc. $100.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388747
Principal investigator 1 Daiichi Sankyo Inc. $115.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388749
Principal investigator 1 Daiichi Sankyo Inc. $624.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388751
Principal investigator 1 Daiichi Sankyo Inc. $85.00 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388753
Principal investigator 1 Daiichi Sankyo Inc. $6,817.50 10/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389769
Principal investigator 1 Incyte Corporation $191.00 10/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611477
Principal investigator 1 Incyte Corporation $263.00 10/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611546
Principal investigator 1 Incyte Corporation $61.00 10/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611573
Principal investigator 1 Incyte Corporation $61.00 10/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611577
Principal investigator 1 Incyte Corporation $32.00 10/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611694
Principal investigator 1 Incyte Corporation $32.00 10/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611698
Principal investigator 1 Incyte Corporation $32.00 10/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611702
Principal investigator 1 Incyte Corporation $130.00 10/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611969
Principal investigator 1 Incyte Corporation $128.00 10/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611972
Principal investigator 1 Incyte Corporation $74.00 10/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240612307
Principal investigator 1 Incyte Corporation $74.00 10/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240612311
Principal investigator 1 Incyte Corporation $74.00 10/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240612314
Principal investigator 1 Incyte Corporation $1,930.00 10/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612530
Principal investigator 1 Incyte Corporation $978.00 10/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612538
Principal investigator 1 Incyte Corporation $264.21 10/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240612615
Principal investigator 1 Incyte Corporation $468.00 10/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240612872
Principal investigator 1 Incyte Corporation $310.00 10/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240612877
Principal investigator 1 Incyte Corporation $310.00 10/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240612883
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 10/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577736
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 10/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577738
Principal investigator 1 Boehringer Ingelheim Espana S.A. $107.76 10/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577740
Principal investigator 1 Boehringer Ingelheim Espana S.A. $41.95 10/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577742
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704099
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220704189
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220704191
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 10/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220704193
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,371.00 10/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805311
Principal investigator 1 BeOne Medicines Ltd. $10,716.00 09/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190331735
Principal investigator 1 Boehringer Ingelheim International GmbH $6,142.50 09/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704307
Principal investigator 1 Boehringer Ingelheim International GmbH $133.41 09/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704431
Principal investigator 1 Boehringer Ingelheim International GmbH $133.41 09/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704433
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $450,234.69 09/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220996758
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $8,126.52 09/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220996864
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $35,108.79 09/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220996866
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $60,947.00 09/29/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804766
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,854.30 09/29/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805309
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,334.00 09/29/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805771
Principal investigator 1 Daiichi Sankyo Inc. $184,128.00 09/29/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388387
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,205.00 09/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804736
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,604.95 09/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804738
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,003.85 09/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804740
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,436.20 09/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804742
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,809.45 09/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804744
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,240.10 09/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804746
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,801.35 09/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804748
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,432.45 09/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804750
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,126.35 09/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804752
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,801.35 09/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804754
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,611.35 09/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804756
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,107.45 09/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804758
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,635.35 09/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804760
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,611.35 09/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804762
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $826.35 09/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804764
Principal investigator 1 Janssen Research & Development, LLC $20,560.00 09/26/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413713
Principal investigator 1 BioNTech SE $2,430.00 09/25/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013001
Principal investigator 1 BioNTech SE $4,213.00 09/25/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013003
Principal investigator 1 BioNTech SE $2,849.00 09/25/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013005
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,425.00 09/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804949
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $30,963.00 09/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805307
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $472.50 09/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805623
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $101,583.90 09/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805625
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $276.97 09/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805739
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $286.97 09/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805741
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $150.00 09/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805743
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $336.79 09/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805745
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $150.00 09/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805747
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $336.98 09/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805749
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,036.00 09/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805751
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $150.00 09/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805753
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,635.70 09/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805755
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,822.50 09/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805757
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,635.70 09/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805759
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,118.70 09/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805761
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,980.70 09/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805763
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $952.20 09/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805765
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,879.40 09/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805767
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,038.42 09/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805769
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $291.50 09/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220996772
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $459.54 09/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220996774
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $693.50 09/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220996776
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $916.05 09/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220996778
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $121.50 09/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220996780
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,317.88 09/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220996782
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $689.00 09/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220996784
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,253.00 09/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805295
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,502.00 09/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805297
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,253.00 09/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805299
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,485.00 09/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805301
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,914.00 09/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805303
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,253.00 09/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805305
Principal investigator 1 BeOne Medicines USA, Inc. $3,000.00 09/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190331959
Principal investigator 1 BeOne Medicines USA, Inc. $1,600.00 09/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190331961
Principal investigator 1 BeOne Medicines USA, Inc. $4,250.00 09/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190331963
Principal investigator 1 BeOne Medicines USA, Inc. $500.00 09/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190331965
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $356.79 09/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805737
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,637.06 09/23/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184241946
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,819.35 09/23/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184241948
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,819.35 09/23/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184241950
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,075.00 09/23/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184241952
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,075.00 09/23/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184241954
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $150.00 09/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805735
Principal investigator 1 Daiichi Sankyo Inc. $32.00 09/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389687
Principal investigator 1 Daiichi Sankyo Inc. $1,013.00 09/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389689
Principal investigator 1 Daiichi Sankyo Inc. $135.00 09/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389691
Principal investigator 1 Daiichi Sankyo Inc. $2,801.00 09/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389693
Principal investigator 1 Daiichi Sankyo Inc. $379.00 09/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389695
Principal investigator 1 Genentech, Inc. $1,613.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211682002
Principal investigator 1 Incyte Corporation $1,894.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611005
Principal investigator 1 Incyte Corporation $2,932.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611008
Principal investigator 1 Incyte Corporation $61.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611046
Principal investigator 1 Incyte Corporation $230.85 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611050
Principal investigator 1 Incyte Corporation $211.95 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611054
Principal investigator 1 Incyte Corporation $100.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611073
Principal investigator 1 Incyte Corporation $74.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611077
Principal investigator 1 Incyte Corporation $32.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611081
Principal investigator 1 Incyte Corporation $196.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611086
Principal investigator 1 Incyte Corporation $3,051.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611174
Principal investigator 1 Incyte Corporation $3,687.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611178
Principal investigator 1 Incyte Corporation $3,487.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611182
Principal investigator 1 Incyte Corporation $2,090.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611186
Principal investigator 1 Incyte Corporation $2,896.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611190
Principal investigator 1 Incyte Corporation $1,894.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611194
Principal investigator 1 Incyte Corporation $1,845.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611200
Principal investigator 1 Incyte Corporation $3,051.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611204
Principal investigator 1 Incyte Corporation $3,687.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611208
Principal investigator 1 Incyte Corporation $3,487.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611212
Principal investigator 1 Incyte Corporation $2,090.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611216
Principal investigator 1 Incyte Corporation $2,896.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611220
Principal investigator 1 Incyte Corporation $2,932.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611225
Principal investigator 1 Incyte Corporation $1,894.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611229
Principal investigator 1 Incyte Corporation $1,845.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611234
Principal investigator 1 Incyte Corporation $3,687.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611238
Principal investigator 1 Incyte Corporation $3,687.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611242
Principal investigator 1 Incyte Corporation $2,090.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611246
Principal investigator 1 Incyte Corporation $2,896.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611250
Principal investigator 1 Incyte Corporation $1,894.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611254
Principal investigator 1 Incyte Corporation $1,845.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611257
Principal investigator 1 Incyte Corporation $2,896.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611262
Principal investigator 1 Incyte Corporation $9,920.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611266
Principal investigator 1 Incyte Corporation $6,278.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611276
Principal investigator 1 Incyte Corporation $6,278.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611280
Principal investigator 1 Incyte Corporation $101.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611291
Principal investigator 1 Incyte Corporation $3,051.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611299
Principal investigator 1 Incyte Corporation $3,051.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611303
Principal investigator 1 Incyte Corporation $3,051.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611308
Principal investigator 1 Incyte Corporation $61.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611316
Principal investigator 1 Incyte Corporation $2,896.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611323
Principal investigator 1 Incyte Corporation $539.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611330
Principal investigator 1 Incyte Corporation $2,697.90 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611335
Principal investigator 1 Incyte Corporation $9,920.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611339
Principal investigator 1 Incyte Corporation $9,920.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611343
Principal investigator 1 Incyte Corporation $9,920.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611347
Principal investigator 1 Incyte Corporation $1,894.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611351
Principal investigator 1 Incyte Corporation $1,845.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611355
Principal investigator 1 Incyte Corporation $1,845.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1240611358
Principal investigator 1 Janssen Research & Development, LLC $1,396.49 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413660
Principal investigator 1 Janssen Research & Development, LLC $350.00 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413685
Principal investigator 1 Janssen Research & Development, LLC $1,228.41 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413703
Principal investigator 1 Janssen Research & Development, LLC $739.32 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413707
Principal investigator 1 Janssen Research & Development, LLC $291.58 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413821
Principal investigator 1 Janssen Research & Development, LLC $379.72 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413828
Principal investigator 1 Janssen Research & Development, LLC $11,263.07 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413892
Principal investigator 1 Janssen Research & Development, LLC $1,061.75 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413928
Principal investigator 1 Janssen Research & Development, LLC $404.89 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413953
Principal investigator 1 Janssen Research & Development, LLC $1,406.81 09/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413966
Principal investigator 1 BeOne Medicines Ltd. $78,600.00 09/19/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190336886
Principal investigator 1 BeOne Medicines Ltd. $15,720.00 09/19/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190336891
Principal investigator 1 Janssen Research & Development, LLC $13,678.00 09/19/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175414002
Principal investigator 1 Ascendis Pharma Endocrinology Inc $9,560.00 09/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
BelieveIT-201 No dispute reported 06/30/2026 1233997103
Principal investigator 1 BioNTech SE $906.00 09/18/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-01 No dispute reported 06/30/2026 1249012833
Principal investigator 1 BioNTech SE $919.28 09/18/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-01 No dispute reported 06/30/2026 1249012839
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,439.00 09/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805285
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,985.99 09/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805573
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,985.99 09/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805575
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,682.25 09/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805577
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,611.25 09/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805579
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,523.53 09/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805581
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,282.50 09/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805583
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $675.00 09/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805585
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,926.79 09/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805587
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $661.50 09/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805589
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,985.99 09/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805591
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,985.99 09/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805593
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,496.50 09/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805595
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,196.79 09/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805597
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,021.44 09/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805599
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,397.29 09/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805601
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,196.79 09/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805603
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,910.25 09/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805605
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $601.13 09/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805607
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,196.79 09/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805609
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $114.75 09/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805611
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,350.28 09/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805613
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,112.75 09/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805615
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,700.00 09/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805617
Principal investigator 1 BeOne Medicines Ltd. $2,860.00 09/17/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190331797
Principal investigator 1 BeOne Medicines Ltd. $4,364.00 09/17/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190331799
Principal investigator 1 BeOne Medicines Ltd. $4,364.00 09/17/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190331829
Principal investigator 1 BeOne Medicines Ltd. $130.00 09/17/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190343128
Principal investigator 1 BeOne Medicines Ltd. $130.00 09/17/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190343168
Principal investigator 1 BeOne Medicines Ltd. $3,549.00 09/17/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190343234
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,914.00 09/17/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805279
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,914.00 09/17/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805281
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,397.40 09/17/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805283
Principal investigator 1 Incyte Corporation $4,836.00 09/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611097
Principal investigator 1 Incyte Corporation $2,068.00 09/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611101
Principal investigator 1 Incyte Corporation $2,916.00 09/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611116
Principal investigator 1 Incyte Corporation $32.00 09/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611120
Principal investigator 1 Incyte Corporation $263.00 09/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611123
Principal investigator 1 Incyte Corporation $4,836.00 09/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611127
Principal investigator 1 Incyte Corporation $3,040.00 09/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611131
Principal investigator 1 Incyte Corporation $2,068.00 09/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611134
Principal investigator 1 Incyte Corporation $61.00 09/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611138
Principal investigator 1 Incyte Corporation $2,916.00 09/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611141
Principal investigator 1 Incyte Corporation $4,836.00 09/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611145
Principal investigator 1 Incyte Corporation $2,068.00 09/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611157
Principal investigator 1 Incyte Corporation $9,672.00 09/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611160
Principal investigator 1 Incyte Corporation $234.00 09/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611163
Principal investigator 1 Incyte Corporation $2,822.00 09/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611284
Principal investigator 1 Incyte Corporation $2,822.00 09/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611288
Principal investigator 1 Incyte Corporation $3,040.00 09/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611320
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,152.70 09/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804608
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,728.00 09/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804610
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,275.55 09/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804612
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,530.00 09/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804614
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,611.35 09/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804616
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,503.35 09/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804618
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,801.35 09/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804620
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,988.00 09/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804622
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,233.35 09/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804624
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,253.95 09/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804626
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,091.29 09/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805531
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $263.25 09/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805533
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,926.80 09/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805535
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,555.55 09/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805537
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,045.25 09/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805539
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,880.55 09/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805541
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,880.55 09/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805543
Principal investigator 1 BeOne Medicines Ltd. $940.44 09/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190327589
Principal investigator 1 BioNTech SE $77.00 09/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013047
Principal investigator 1 BioNTech SE $405.00 09/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013049
Principal investigator 1 Janssen Research & Development, LLC $147,277.00 09/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413881
Principal investigator 1 BioNTech SE $2,025.00 09/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012765
Principal investigator 1 BioNTech SE $2,700.00 09/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013029
Principal investigator 1 BioNTech SE $4,000.00 09/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013031
Principal investigator 1 BioNTech SE $489.00 09/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013033
Principal investigator 1 BioNTech SE $1,620.00 09/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013035
Principal investigator 1 BioNTech SE $2,025.00 09/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013037
Principal investigator 1 BioNTech SE $1,267.00 09/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013039
Principal investigator 1 BioNTech SE $3,000.00 09/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013041
Principal investigator 1 BioNTech SE $1,505.00 09/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013043
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,914.00 09/12/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805287
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,237.00 09/12/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805289
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,914.00 09/12/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805291
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,633.00 09/12/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805293
Principal investigator 1 Daiichi Sankyo Inc. $78.00 09/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388307
Principal investigator 1 Daiichi Sankyo Inc. $270.00 09/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388313
Principal investigator 1 Daiichi Sankyo Inc. $2,801.00 09/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388315
Principal investigator 1 Daiichi Sankyo Inc. $405.00 09/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388317
Principal investigator 1 Daiichi Sankyo Inc. $42.00 09/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388319
Principal investigator 1 Daiichi Sankyo Inc. $85.00 09/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388321
Principal investigator 1 Daiichi Sankyo Inc. $103.00 09/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388323
Principal investigator 1 Daiichi Sankyo Inc. $641.00 09/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388325
Principal investigator 1 Daiichi Sankyo Inc. $50.00 09/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388327
Principal investigator 1 Daiichi Sankyo Inc. $113.00 09/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388353
Principal investigator 1 Daiichi Sankyo Inc. $80.00 09/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388357
Principal investigator 1 Daiichi Sankyo Inc. $84.00 09/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388359
Principal investigator 1 Daiichi Sankyo Inc. $72.00 09/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388361
Principal investigator 1 Daiichi Sankyo Inc. $135.00 09/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388363
Principal investigator 1 Daiichi Sankyo Inc. $472.00 09/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388365
Principal investigator 1 Daiichi Sankyo Inc. $135.00 09/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388367
Principal investigator 1 Daiichi Sankyo Inc. $34.00 09/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388369
Principal investigator 1 Daiichi Sankyo Inc. $641.00 09/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388371
Principal investigator 1 Daiichi Sankyo Inc. $675.00 09/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388373
Principal investigator 1 Daiichi Sankyo Inc. $58.00 09/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388375
Principal investigator 1 Daiichi Sankyo Inc. $135.00 09/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388377
Principal investigator 1 Daiichi Sankyo Inc. $675.00 09/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388379
Principal investigator 1 Daiichi Sankyo Inc. $105.00 09/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388389
Principal investigator 1 Daiichi Sankyo Inc. $205.00 09/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388393
Principal investigator 1 Daiichi Sankyo Inc. $135.00 09/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388395
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 09/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804724
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 09/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804726
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 09/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804728
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 09/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804730
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,744.75 09/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804732
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 09/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805619
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 09/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805621
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 09/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805501
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 09/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805503
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 09/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805505
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 09/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805507
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 09/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805509
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,056.25 09/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804917
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,056.25 09/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804919
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,056.25 09/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804921
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22,891.95 09/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804923
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,316.00 09/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804925
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,716.20 09/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804927
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,982.25 09/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804929
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $40.43 09/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804931
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,880.25 09/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804933
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,565.05 09/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804935
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,127.95 09/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804937
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $189.00 09/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804939
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,991.40 09/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804941
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $243.50 09/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804943
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,008.15 09/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804945
Principal investigator 1 Daiichi Sankyo Inc. $611.55 09/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388329
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 09/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388331
Principal investigator 1 Daiichi Sankyo Inc. $3,456.00 09/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388333
Principal investigator 1 Daiichi Sankyo Inc. $6,818.00 09/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388335
Principal investigator 1 Daiichi Sankyo Inc. $6,817.50 09/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388337
Principal investigator 1 Daiichi Sankyo Inc. $4,251.00 09/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388339
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 09/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388341
Principal investigator 1 Daiichi Sankyo Inc. $379.00 09/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388343
Principal investigator 1 Daiichi Sankyo Inc. $4,122.00 09/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388345
Principal investigator 1 Daiichi Sankyo Inc. $270.00 09/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388347
Principal investigator 1 Daiichi Sankyo Inc. $675.00 09/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388349
Principal investigator 1 Daiichi Sankyo Inc. $675.00 09/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388351
Principal investigator 1 Daiichi Sankyo Inc. $4,200.00 09/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388381
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 09/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388383
Principal investigator 1 Daiichi Sankyo Inc. $3,375.00 09/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388385
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $19,378.55 09/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805257
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $750.00 09/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805259
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,750.00 09/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805261
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $150.00 09/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805263
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,150.00 09/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805265
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,557.00 09/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805267
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,900.00 09/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805269
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $17,064.00 09/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805271
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,050.00 09/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805273
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $68.00 09/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805275
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $168.00 09/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805277
Principal investigator 1 Incyte Corporation $1,750.00 09/05/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611031
Principal investigator 1 Incyte Corporation $3,300.00 09/05/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611035
Principal investigator 1 Incyte Corporation $2,000.00 09/05/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611043
Principal investigator 1 Incyte Corporation $4,000.00 09/05/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611057
Principal investigator 1 ABBVIE INC. $7,965.00 09/04/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202508846
Principal investigator 1 ABBVIE INC. $35,511.08 09/04/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-4) No dispute reported 06/30/2026 1202508848
Principal investigator 1 ABBVIE INC. $8,049.98 09/04/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202508934
Principal investigator 1 ABBVIE INC. $15,313.05 09/04/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202508936
Principal investigator 1 BioNTech SE $21,089.00 09/04/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012859
Principal investigator 1 BioNTech SE $21,089.00 09/04/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012861
Principal investigator 1 BioNTech SE $21,089.00 09/04/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012965
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804632
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804634
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804636
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804638
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,284.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804640
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804642
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804644
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804646
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804648
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804650
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,240.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804652
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804654
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804656
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,164.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804658
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,164.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804660
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,164.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804662
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,548.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804664
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,548.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804666
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,548.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804668
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,548.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804670
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,548.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804672
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,240.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804674
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,548.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804676
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,284.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804678
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,240.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804680
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,284.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804682
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,548.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804684
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,548.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804686
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,164.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804688
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,548.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804690
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804692
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804694
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804696
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804698
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804700
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804702
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804704
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,284.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804706
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,240.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804708
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,284.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804710
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,548.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804712
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,164.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804714
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,284.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804716
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,548.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804718
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,240.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804720
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,240.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804722
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,056.25 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804947
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $19,941.52 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805563
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $19,334.03 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805565
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $341.60 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805567
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $324.20 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805569
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $405.52 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805571
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,334.00 09/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805733
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,661.42 09/04/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184235401
Principal investigator 1 Boehringer Ingelheim International GmbH $355.00 09/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704079
Principal investigator 1 Boehringer Ingelheim International GmbH $9,945.00 09/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704081
Principal investigator 1 Boehringer Ingelheim International GmbH $9,694.00 09/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704083
Principal investigator 1 Boehringer Ingelheim International GmbH $5,346.00 09/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704085
Principal investigator 1 Boehringer Ingelheim International GmbH $790.00 09/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704087
Principal investigator 1 Boehringer Ingelheim International GmbH $145.00 09/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704089
Principal investigator 1 Boehringer Ingelheim International GmbH $47.00 09/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704091
Principal investigator 1 Boehringer Ingelheim International GmbH $1,986.00 09/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704093
Principal investigator 1 Boehringer Ingelheim International GmbH $1,986.00 09/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704095
Principal investigator 1 Boehringer Ingelheim International GmbH $355.00 09/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704097
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,709.55 09/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804734
Principal investigator 1 Daiichi Sankyo Inc. $97.00 09/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389707
Principal investigator 1 Daiichi Sankyo Inc. $115.00 09/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389709
Principal investigator 1 Daiichi Sankyo Inc. $6,075.00 09/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389749
Principal investigator 1 Incyte Corporation $6,000.00 09/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611039
Principal investigator 1 Incyte Corporation $176.89 09/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611269
Principal investigator 1 BeOne Medicines Ltd. $3,440.00 09/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190331733
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577732
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577734
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704039
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220704185
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220704187
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $597,154.00 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804606
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $810.00 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805159
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $810.00 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805161
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $810.00 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805163
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14,945.00 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805165
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,633.00 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805167
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,049.94 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805169
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,224.50 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805171
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $100.00 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805173
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $494.05 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805175
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $415.00 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805177
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,092.00 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805179
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,018.75 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805181
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $640.00 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805183
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $673.00 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805185
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,498.30 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805187
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,016.00 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805189
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,143.00 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805191
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,818.00 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805193
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $121.70 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805195
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $136.00 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805197
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,007.00 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805199
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $336.00 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805201
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,301.00 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805203
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,801.00 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805205
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $283.00 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805207
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,521.00 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805209
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,307.75 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805211
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,375.00 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805213
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $824.53 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805483
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,724.38 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805485
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,852.03 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805487
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $845.53 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805489
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,004.15 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805491
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,844.53 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805493
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,683.28 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805495
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,270.03 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805497
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,640.78 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805499
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $45,724.00 09/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805731
Principal investigator 1 Janssen Research & Development, LLC $55,701.00 09/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413667
Principal investigator 1 Boehringer Ingelheim International GmbH $2,250.00 08/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704303
Principal investigator 1 Boehringer Ingelheim International GmbH $734.05 08/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704305
Principal investigator 1 Boehringer Ingelheim International GmbH $133.41 08/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704445
Principal investigator 1 Boehringer Ingelheim International GmbH $133.41 08/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704447
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,358.00 08/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220804813
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $24,522.00 08/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804915
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $55,373.00 08/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805231
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $52,953.30 08/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805481
Principal investigator 1 BeOne Medicines Ltd. $32,322.30 08/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190344615
Principal investigator 1 Boehringer Ingelheim International GmbH $93.28 08/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704435
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 08/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704437
Principal investigator 1 Boehringer Ingelheim International GmbH $1.00 08/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704439
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $8,859.59 08/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220996844
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $863.23 08/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220996846
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $5,754.14 08/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220996848
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $339.40 08/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220996874
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $199.80 08/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220996876
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $14.60 08/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220996878
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $702.77 08/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805227
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $115.09 08/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805229
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,100.66 08/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805475
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $754.65 08/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805477
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,827.00 08/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805479
Principal investigator 1 Genentech, Inc. $1,913.00 08/26/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211681982
Principal investigator 1 Genentech, Inc. $19,098.89 08/26/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211682008
Principal investigator 1 Genentech, Inc. $29,440.55 08/26/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211682010
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,709.55 08/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804630
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $100.00 08/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805235
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,768.30 08/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805237
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,241.85 08/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805239
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $120.00 08/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805241
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,548.00 08/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805243
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 08/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805245
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,498.30 08/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805247
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,498.30 08/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805249
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $675.00 08/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805251
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,179.30 08/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805253
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $162.82 08/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805255
Principal investigator 1 Daiichi Sankyo Inc. $74.50 08/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388309
Principal investigator 1 Daiichi Sankyo Inc. $119.20 08/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388311
Principal investigator 1 Daiichi Sankyo Inc. $74.50 08/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388355
Principal investigator 1 Daiichi Sankyo Inc. $74.50 08/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388391
Principal investigator 1 Genentech, Inc. $263.00 08/25/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211681984
Principal investigator 1 Genentech, Inc. $340.00 08/25/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211681986
Principal investigator 1 Genentech, Inc. $1,675.00 08/25/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211681988
Principal investigator 1 Genentech, Inc. $571.00 08/25/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211681990
Principal investigator 1 Genentech, Inc. $1,913.00 08/25/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211681992
Principal investigator 1 Genentech, Inc. $348.00 08/25/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211681994
Principal investigator 1 Genentech, Inc. $409.00 08/25/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211681996
Principal investigator 1 Genentech, Inc. $340.00 08/25/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211681998
Principal investigator 1 Genentech, Inc. $2,548.00 08/25/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211682000
Principal investigator 1 Genentech, Inc. $2,429.00 08/25/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211682004
Principal investigator 1 Janssen Research & Development, LLC $2,540.00 08/25/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413809
Principal investigator 1 Janssen Research & Development, LLC $20,560.00 08/25/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413904
Principal investigator 1 Janssen Research & Development, LLC $5,950.00 08/25/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413943
Principal investigator 1 Janssen Research & Development, LLC $27,636.00 08/25/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413986
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,709.55 08/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804628
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $369.90 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805435
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,116.25 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805437
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $780.42 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805439
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,049.75 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805441
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,085.28 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805443
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,170.78 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805445
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,580.48 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805447
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,447.43 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805449
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,997.78 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805451
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,985.85 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805453
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,045.25 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805455
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,323.35 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805457
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,625.75 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805459
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,120.85 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805461
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,523.03 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805463
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,247.90 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805465
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,099.25 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805467
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $546.10 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805469
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,997.89 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805471
Principal investigator 1 Daiichi Sankyo Inc. $135.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389605
Principal investigator 1 Daiichi Sankyo Inc. $135.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389633
Principal investigator 1 Daiichi Sankyo Inc. $32.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389635
Principal investigator 1 Daiichi Sankyo Inc. $135.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389637
Principal investigator 1 Daiichi Sankyo Inc. $1,013.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389639
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389641
Principal investigator 1 Daiichi Sankyo Inc. $54.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389643
Principal investigator 1 Daiichi Sankyo Inc. $32.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389645
Principal investigator 1 Daiichi Sankyo Inc. $61.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389647
Principal investigator 1 Daiichi Sankyo Inc. $1,013.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389649
Principal investigator 1 Daiichi Sankyo Inc. $32.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389651
Principal investigator 1 Daiichi Sankyo Inc. $205.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389653
Principal investigator 1 Daiichi Sankyo Inc. $135.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389655
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389657
Principal investigator 1 Daiichi Sankyo Inc. $1,013.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389659
Principal investigator 1 Daiichi Sankyo Inc. $205.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389661
Principal investigator 1 Daiichi Sankyo Inc. $32.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389663
Principal investigator 1 Daiichi Sankyo Inc. $32.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389697
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389699
Principal investigator 1 Daiichi Sankyo Inc. $1,013.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389701
Principal investigator 1 Daiichi Sankyo Inc. $135.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389703
Principal investigator 1 Daiichi Sankyo Inc. $135.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389705
Principal investigator 1 Daiichi Sankyo Inc. $32.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389711
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389713
Principal investigator 1 Daiichi Sankyo Inc. $32.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389715
Principal investigator 1 Daiichi Sankyo Inc. $2,801.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389717
Principal investigator 1 Daiichi Sankyo Inc. $135.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389719
Principal investigator 1 Daiichi Sankyo Inc. $1,013.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389721
Principal investigator 1 Daiichi Sankyo Inc. $1,013.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389723
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389739
Principal investigator 1 Daiichi Sankyo Inc. $135.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389741
Principal investigator 1 Daiichi Sankyo Inc. $624.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389745
Principal investigator 1 Daiichi Sankyo Inc. $32.00 08/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389753
Principal investigator 1 BioNTech SE $27,029.00 08/21/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012967
Principal investigator 1 BioNTech SE $7,560.00 08/21/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012973
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,007.45 08/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804594
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $749.30 08/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804596
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $17,093.70 08/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804598
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 08/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804600
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,384.15 08/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804602
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $17,093.70 08/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804604
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,752.54 08/21/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184229905
Principal investigator 1 BeOne Medicines Ltd. $31,440.00 08/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190342203
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $413.75 08/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805157
Principal investigator 1 Genentech, Inc. $19,800.00 08/20/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Optimization of the CRS Profile for Glofit+GemOx in R/R DLBCL No dispute reported 06/30/2026 1211681954
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,506.00 08/19/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805155
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 08/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805215
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $19,063.00 08/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805217
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14,810.00 08/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805219
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,146.50 08/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805221
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,658.45 08/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805223
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,772.14 08/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805225
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,269.40 08/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805473
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,103.00 08/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804909
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,389.00 08/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804911
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $817.00 08/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804913
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,002.00 08/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804907
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,637.06 08/14/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184228593
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,298.00 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805103
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805105
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805107
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805109
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805111
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805113
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805115
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805117
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805119
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805121
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805123
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805125
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805127
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805129
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805131
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805133
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,205.35 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805135
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,565.80 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805137
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,722.40 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805139
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,498.30 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805141
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,651.80 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805143
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805145
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,205.35 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805147
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,565.80 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805149
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,610.35 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805151
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,498.30 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805153
Principal investigator 1 Daiichi Sankyo Inc. $2,801.00 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389615
Principal investigator 1 Daiichi Sankyo Inc. $1,013.00 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389617
Principal investigator 1 Daiichi Sankyo Inc. $6,075.00 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389619
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389725
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389727
Principal investigator 1 Daiichi Sankyo Inc. $675.00 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389729
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 08/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389755
Principal investigator 1 Incyte Corporation $440.00 08/13/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611148
Principal investigator 1 Incyte Corporation $240.00 08/13/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611153
Principal investigator 1 Incyte Corporation $1,000.00 08/13/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611167
Principal investigator 1 Incyte Corporation $2,780.00 08/13/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611171
Principal investigator 1 Incyte Corporation $1,400.00 08/13/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611272
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $10,631.51 08/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220996838
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $863.23 08/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220996840
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $5,754.14 08/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220996842
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 08/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389609
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 08/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389611
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 08/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389613
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $31,189.33 08/08/2025 Non-covered Recipient Entity
Valkyrie Global, Inc
A Phase 1, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination with Chemotherapy or Nivolumab in Advanced Solid Tumors No dispute reported 06/30/2026 1235992019
Principal investigator 1 Genentech, Inc. $1,419.00 08/08/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211682006
Principal investigator 1 BioNTech SE $3,780.00 08/07/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012971
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,577.00 08/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220804815
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $29,000.00 08/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220804817
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,410.25 08/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805233
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,750.00 08/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805545
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $779.89 08/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805547
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22,763.03 08/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805549
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,894.87 08/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805551
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $622.50 08/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805553
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,892.85 08/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805555
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $568.43 08/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805557
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $622.50 08/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805559
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $422.12 08/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805561
Principal investigator 1 Daiichi Sankyo Inc. $3,240.00 08/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388573
Principal investigator 1 Daiichi Sankyo Inc. $3,500.00 08/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388613
Principal investigator 1 Daiichi Sankyo Inc. $2,668.00 08/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388615
Principal investigator 1 Daiichi Sankyo Inc. $3,375.00 08/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388617
Principal investigator 1 Daiichi Sankyo Inc. $4,050.00 08/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388619
Principal investigator 1 Daiichi Sankyo Inc. $2,000.00 08/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388621
Principal investigator 1 Daiichi Sankyo Inc. $743.00 08/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388623
Principal investigator 1 Daiichi Sankyo Inc. $1,920.00 08/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388625
Principal investigator 1 Daiichi Sankyo Inc. $1,750.00 08/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388627
Principal investigator 1 Daiichi Sankyo Inc. $1,750.00 08/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388629
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 08/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388631
Principal investigator 1 Daiichi Sankyo Inc. $205.00 08/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389671
Principal investigator 1 Daiichi Sankyo Inc. $32.00 08/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389673
Principal investigator 1 Daiichi Sankyo Inc. $55.00 08/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389675
Principal investigator 1 Daiichi Sankyo Inc. $462.00 08/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389677
Principal investigator 1 Daiichi Sankyo Inc. $100.00 08/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389679
Principal investigator 1 Daiichi Sankyo Inc. $61.00 08/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389681
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389683
Principal investigator 1 Daiichi Sankyo Inc. $57.00 08/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389743
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,202.00 08/07/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184226503
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,819.35 08/07/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184226505
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $273.90 08/07/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184226507
Principal investigator 1 ABBVIE INC. $50,336.10 08/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202502608
Principal investigator 1 ABBVIE INC. $56,655.48 08/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-4) No dispute reported 06/30/2026 1202502610
Principal investigator 1 Boehringer Ingelheim International GmbH $203.00 08/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704043
Principal investigator 1 Boehringer Ingelheim International GmbH $2,487.00 08/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704045
Principal investigator 1 Boehringer Ingelheim International GmbH $829.00 08/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704047
Principal investigator 1 Boehringer Ingelheim International GmbH $236.00 08/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704049
Principal investigator 1 Boehringer Ingelheim International GmbH $101.00 08/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704051
Principal investigator 1 Boehringer Ingelheim International GmbH $236.00 08/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704053
Principal investigator 1 Boehringer Ingelheim International GmbH $675.00 08/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704055
Principal investigator 1 Boehringer Ingelheim International GmbH $101.00 08/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704057
Principal investigator 1 Boehringer Ingelheim International GmbH $155.00 08/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704059
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 08/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704061
Principal investigator 1 Boehringer Ingelheim International GmbH $7.00 08/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704063
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 08/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704065
Principal investigator 1 Boehringer Ingelheim International GmbH $68.00 08/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704067
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 08/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704069
Principal investigator 1 Boehringer Ingelheim International GmbH $567.68 08/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704071
Principal investigator 1 Boehringer Ingelheim International GmbH $68.00 08/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704075
Principal investigator 1 Boehringer Ingelheim International GmbH $155.00 08/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704077
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 08/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389665
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 08/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389667
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 08/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389669
Principal investigator 1 Daiichi Sankyo Inc. $4,143.00 08/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389747
Principal investigator 1 Incyte Corporation $5,250.00 08/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611012
Principal investigator 1 Incyte Corporation $1,250.00 08/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611016
Principal investigator 1 Incyte Corporation $4,842.00 08/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611021
Principal investigator 1 Incyte Corporation $307.90 08/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611023
Principal investigator 1 Incyte Corporation $1,750.00 08/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611027
Principal investigator 1 Incyte Corporation $3,475.00 08/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611295
Principal investigator 1 Incyte Corporation $300.00 08/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611313
Principal investigator 1 BeOne Medicines Ltd. $12,114.12 08/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190344541
Principal investigator 1 BeOne Medicines Ltd. $257.00 08/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190344603
Principal investigator 1 BeOne Medicines Ltd. $660.00 08/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190344607
Principal investigator 1 BeOne Medicines Ltd. $660.00 08/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190344611
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $190.79 08/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804588
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,106.35 08/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804590
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $582.02 08/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804592
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,075.00 08/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805511
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,750.00 08/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805513
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,750.00 08/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805515
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,750.00 08/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805517
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,376.47 08/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805519
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,376.48 08/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805521
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,593.91 08/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805523
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,376.48 08/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805525
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $19,941.53 08/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805527
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $19,941.53 08/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805529
Principal investigator 1 BioNTech SE $1,890.00 08/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013007
Principal investigator 1 BioNTech SE $4,532.00 08/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013051
Principal investigator 1 BioNTech SE $3,686.00 08/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013053
Principal investigator 1 BioNTech SE $4,018.00 08/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013055
Principal investigator 1 BioNTech SE $4,030.00 08/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013057
Principal investigator 1 BioNTech SE $129.00 08/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013059
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577728
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577730
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704037
Principal investigator 1 Boehringer Ingelheim International GmbH $145.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704073
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220704181
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220704183
Principal investigator 1 Daiichi Sankyo Inc. $80.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388499
Principal investigator 1 Daiichi Sankyo Inc. $257.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388501
Principal investigator 1 Daiichi Sankyo Inc. $169.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388503
Principal investigator 1 Daiichi Sankyo Inc. $103.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388505
Principal investigator 1 Daiichi Sankyo Inc. $57.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388519
Principal investigator 1 Daiichi Sankyo Inc. $105.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388521
Principal investigator 1 Daiichi Sankyo Inc. $55.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388523
Principal investigator 1 Daiichi Sankyo Inc. $100.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388525
Principal investigator 1 Daiichi Sankyo Inc. $85.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388527
Principal investigator 1 Daiichi Sankyo Inc. $405.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388529
Principal investigator 1 Daiichi Sankyo Inc. $42.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388531
Principal investigator 1 Daiichi Sankyo Inc. $72.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388533
Principal investigator 1 Daiichi Sankyo Inc. $203.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388535
Principal investigator 1 Daiichi Sankyo Inc. $540.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388537
Principal investigator 1 Daiichi Sankyo Inc. $84.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388539
Principal investigator 1 Daiichi Sankyo Inc. $58.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388541
Principal investigator 1 Daiichi Sankyo Inc. $675.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388543
Principal investigator 1 Daiichi Sankyo Inc. $135.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388545
Principal investigator 1 Daiichi Sankyo Inc. $115.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388547
Principal investigator 1 Daiichi Sankyo Inc. $55.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388549
Principal investigator 1 Daiichi Sankyo Inc. $135.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388551
Principal investigator 1 Daiichi Sankyo Inc. $113.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388553
Principal investigator 1 Daiichi Sankyo Inc. $58.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388555
Principal investigator 1 Daiichi Sankyo Inc. $135.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388557
Principal investigator 1 Daiichi Sankyo Inc. $50.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388633
Principal investigator 1 Daiichi Sankyo Inc. $205.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388637
Principal investigator 1 Daiichi Sankyo Inc. $379.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388641
Principal investigator 1 Daiichi Sankyo Inc. $15,000.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389631
Principal investigator 1 Daiichi Sankyo Inc. $4,127.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389735
Principal investigator 1 Daiichi Sankyo Inc. $6,750.00 08/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389737
Principal investigator 1 ABBVIE INC. $26,611.20 07/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202500640
Principal investigator 1 BioNTech SE $135.00 07/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012845
Principal investigator 1 BioNTech SE $135.00 07/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012847
Principal investigator 1 BioNTech SE $135.00 07/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012849
Principal investigator 1 BioNTech SE $135.00 07/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012851
Principal investigator 1 BioNTech SE $115.00 07/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012853
Principal investigator 1 BioNTech SE $115.00 07/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012855
Principal investigator 1 BioNTech SE $115.00 07/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012857
Principal investigator 1 BioNTech SE $203.00 07/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012863
Principal investigator 1 BioNTech SE $405.00 07/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012865
Principal investigator 1 BioNTech SE $135.00 07/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012951
Principal investigator 1 BioNTech SE $182.00 07/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012953
Principal investigator 1 BioNTech SE $270.00 07/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012955
Principal investigator 1 BioNTech SE $3,176.00 07/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012957
Principal investigator 1 BioNTech SE $149.00 07/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012959
Principal investigator 1 BioNTech SE $380.00 07/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012961
Principal investigator 1 BioNTech SE $115.00 07/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012963
Principal investigator 1 BioNTech SE $254.00 07/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012969
Principal investigator 1 BioNTech SE $203.00 07/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012975
Principal investigator 1 BioNTech SE $405.00 07/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012977
Principal investigator 1 BioNTech SE $101.00 07/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012979
Principal investigator 1 BioNTech SE $47.00 07/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012981
Principal investigator 1 Boehringer Ingelheim International GmbH $25,062.53 07/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704259
Principal investigator 1 Boehringer Ingelheim International GmbH $27,490.66 07/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704261
Principal investigator 1 Boehringer Ingelheim International GmbH $27,923.50 07/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704263
Principal investigator 1 Boehringer Ingelheim International GmbH $26,492.18 07/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704265
Principal investigator 1 Boehringer Ingelheim International GmbH $24,992.95 07/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704267
Principal investigator 1 Boehringer Ingelheim International GmbH $26,107.73 07/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704269
Principal investigator 1 Boehringer Ingelheim International GmbH $32,844.87 07/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704271
Principal investigator 1 Boehringer Ingelheim International GmbH $25,595.00 07/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704273
Principal investigator 1 Boehringer Ingelheim International GmbH $18,427.50 07/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704275
Principal investigator 1 Boehringer Ingelheim International GmbH $147,608.34 07/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704277
Principal investigator 1 Boehringer Ingelheim International GmbH $20,250.00 07/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704279
Principal investigator 1 Boehringer Ingelheim International GmbH $13,821.30 07/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704281
Principal investigator 1 Boehringer Ingelheim International GmbH $20,250.00 07/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704283
Principal investigator 1 Boehringer Ingelheim International GmbH $20,250.00 07/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704285
Principal investigator 1 Boehringer Ingelheim International GmbH $16,726.50 07/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704287
Principal investigator 1 Boehringer Ingelheim International GmbH $20,250.00 07/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704289
Principal investigator 1 Boehringer Ingelheim International GmbH $20,250.00 07/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704291
Principal investigator 1 Boehringer Ingelheim International GmbH $20,250.00 07/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704293
Principal investigator 1 Boehringer Ingelheim International GmbH $20,250.00 07/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704295
Principal investigator 1 Boehringer Ingelheim International GmbH $16,368.75 07/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704297
Principal investigator 1 Boehringer Ingelheim International GmbH $20,250.00 07/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704299
Principal investigator 1 Boehringer Ingelheim International GmbH $13,213.80 07/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704301
Principal investigator 1 Boehringer Ingelheim International GmbH $133.41 07/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704423
Principal investigator 1 Boehringer Ingelheim International GmbH $133.41 07/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704425
Principal investigator 1 Boehringer Ingelheim International GmbH $82.10 07/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704427
Principal investigator 1 Boehringer Ingelheim International GmbH $35.92 07/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704429
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $753.26 07/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804586
Principal investigator 1 AstraZeneca UK Limited $157,266.75 07/30/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
a phase 2,open label study to evaluate the safety,tolerability,pharmacokinetics,immunogenicity,and antitumor activity of volrustomig priming regimen in combination with other anticancer agents in participants with solid tumors evolve 01 No dispute reported 06/30/2026 1185552417
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $314.09 07/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805097
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $238.05 07/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805099
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $317.08 07/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805101
Principal investigator 1 BeOne Medicines USA, Inc. $523.00 07/29/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190331957
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $377.39 07/29/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804903
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,850.48 07/29/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804905
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,179.30 07/29/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805095
Principal investigator 1 Genentech, Inc. $15,470.00 07/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Optimization of the CRS Profile for Glofit+GemOx in R/R DLBCL No dispute reported 06/30/2026 1211681950
Principal investigator 1 Genentech, Inc. $20,184.00 07/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Optimization of the CRS Profile for Glofit+GemOx in R/R DLBCL No dispute reported 06/30/2026 1211681952
Principal investigator 1 Genentech, Inc. $39,769.00 07/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211681972
Principal investigator 1 BioNTech SE $4,532.00 07/28/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013009
Principal investigator 1 BioNTech SE $4,018.00 07/28/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013011
Principal investigator 1 BioNTech SE $4,030.00 07/28/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013013
Principal investigator 1 BioNTech SE $129.00 07/28/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013015
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $509.10 07/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220996868
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $299.70 07/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220996870
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $21.90 07/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220996872
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,981.95 07/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805065
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $70.00 07/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805067
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,069.10 07/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805069
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $488.50 07/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805071
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $120.00 07/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805073
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $170.00 07/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805075
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 07/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805077
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $100.00 07/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805079
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,082.85 07/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805081
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20.00 07/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805083
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $70.00 07/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805085
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,981.95 07/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805087
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,019.10 07/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805089
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,179.30 07/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805091
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,179.30 07/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805093
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,993.00 07/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805729
Principal investigator 1 Janssen Research & Development, LLC $20,560.00 07/28/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413655
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,101.16 07/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805063
Principal investigator 1 Daiichi Sankyo Inc. $135.00 07/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388579
Principal investigator 1 Daiichi Sankyo Inc. $213.00 07/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388581
Principal investigator 1 Daiichi Sankyo Inc. $100.00 07/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388583
Principal investigator 1 Daiichi Sankyo Inc. $135.00 07/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388585
Principal investigator 1 Daiichi Sankyo Inc. $198.00 07/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388587
Principal investigator 1 Daiichi Sankyo Inc. $55.00 07/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388589
Principal investigator 1 Daiichi Sankyo Inc. $57.00 07/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388591
Principal investigator 1 Daiichi Sankyo Inc. $55.00 07/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388593
Principal investigator 1 ABBVIE INC. $14,623.00 07/24/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202499634
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $710.20 07/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804582
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,968.74 07/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804584
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $421.76 07/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805047
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $35.59 07/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805049
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $402.65 07/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805051
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $239.68 07/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805053
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $202.82 07/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805055
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $259.26 07/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805057
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14,810.00 07/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805059
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $581.73 07/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805061
Principal investigator 1 PFIZER INC. $2,257.20 07/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228715241
Principal investigator 1 BeOne Medicines Ltd. $2,391.00 07/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190327591
Principal investigator 1 BeOne Medicines Ltd. $1,863.00 07/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190327593
Principal investigator 1 BeOne Medicines Ltd. $11,181.00 07/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190331739
Principal investigator 1 BeOne Medicines Ltd. $2,482.00 07/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190344592
Principal investigator 1 BeOne Medicines Ltd. $2,906.00 07/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190344598
Principal investigator 1 BeOne Medicines Ltd. $11,201.62 07/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190344622
Principal investigator 1 BeOne Medicines Ltd. $1,326.00 07/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190344627
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,892.95 07/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804901
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,498.30 07/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805041
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,972.30 07/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805043
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,615.50 07/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805045
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,333.54 07/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805727
Principal investigator 1 Genentech, Inc. $9,900.00 07/23/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211681970
Principal investigator 1 Genentech, Inc. $16,582.00 07/23/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211681974
Principal investigator 1 Genentech, Inc. $1,500.00 07/23/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211681976
Principal investigator 1 Genentech, Inc. $9,900.00 07/23/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211681978
Principal investigator 1 BioNTech SE $14,098.00 07/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-01 No dispute reported 06/30/2026 1249012835
Principal investigator 1 BioNTech SE $129.00 07/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-01 No dispute reported 06/30/2026 1249012837
Principal investigator 1 Genentech, Inc. $76,672.00 07/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Optimization of the CRS Profile for Glofit+GemOx in R/R DLBCL No dispute reported 06/30/2026 1211681946
Principal investigator 1 Janssen Research & Development, LLC $22,162.00 07/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413672
Principal investigator 1 Janssen Research & Development, LLC $32,236.00 07/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413991
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,389.60 07/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184217635
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $101,250.00 07/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805433
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,693.00 07/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805705
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,641.00 07/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805707
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,641.00 07/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805709
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,641.00 07/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805711
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,641.00 07/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805713
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,334.00 07/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805715
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,334.00 07/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805717
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,041.00 07/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805719
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,000.00 07/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805721
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,334.00 07/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805723
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,000.00 07/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805725
Principal investigator 1 Daiichi Sankyo Inc. $5,333.00 07/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388565
Principal investigator 1 Daiichi Sankyo Inc. $6,615.00 07/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388567
Principal investigator 1 Daiichi Sankyo Inc. $6,075.00 07/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388569
Principal investigator 1 Daiichi Sankyo Inc. $6,210.00 07/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388571
Principal investigator 1 Incyte Corporation $2,822.00 07/18/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611062
Principal investigator 1 Incyte Corporation $675.00 07/18/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611066
Principal investigator 1 Incyte Corporation $2,060.20 07/18/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611069
Principal investigator 1 Incyte Corporation $2,916.00 07/18/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611083
Principal investigator 1 Incyte Corporation $2,822.00 07/18/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611090
Principal investigator 1 Incyte Corporation $675.00 07/18/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611093
Principal investigator 1 Incyte Corporation $2,068.00 07/18/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611105
Principal investigator 1 Incyte Corporation $3,040.00 07/18/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611108
Principal investigator 1 Incyte Corporation $2,916.00 07/18/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611112
Principal investigator 1 Incyte Corporation $3,040.00 07/18/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240611326
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,075.00 07/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184217012
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,075.00 07/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184217014
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $491.40 07/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184217016
Principal investigator 1 BioNTech SE $405.00 07/16/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013045
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,709.55 07/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804572
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $810.00 07/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804574
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,000.00 07/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804576
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $16,519.95 07/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804578
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $17,093.70 07/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804580
Principal investigator 1 Daiichi Sankyo Inc. $675.00 07/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388507
Principal investigator 1 Daiichi Sankyo Inc. $55.00 07/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388509
Principal investigator 1 Daiichi Sankyo Inc. $135.00 07/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388511
Principal investigator 1 Daiichi Sankyo Inc. $135.00 07/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388513
Principal investigator 1 Daiichi Sankyo Inc. $55.00 07/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388515
Principal investigator 1 Daiichi Sankyo Inc. $57.00 07/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388517
Principal investigator 1 Daiichi Sankyo Inc. $100.00 07/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388635
Principal investigator 1 PFIZER INC. $17,841.00 07/16/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228847914
Recipient Regeneron Pharmaceuticals, Inc. $225.68 07/16/2025 Covered Recipient Physician A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184115625
Principal investigator 1 ABBVIE INC. $5,265.00 07/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202498282
Principal investigator 1 ABBVIE INC. $31,641.86 07/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-4) No dispute reported 06/30/2026 1202498284
Principal investigator 1 BeOne Medicines Ltd. $11,373.12 07/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190344618
Principal investigator 1 BioNTech SE $176.70 07/15/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-01 No dispute reported 06/30/2026 1249012831
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,403,579.00 07/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804570
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,693.00 07/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805695
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,693.00 07/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805697
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,693.00 07/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805699
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,693.00 07/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805701
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,693.00 07/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805703
Principal investigator 1 BioNTech SE $4,532.00 07/14/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013017
Principal investigator 1 BioNTech SE $3,686.00 07/14/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013019
Principal investigator 1 BioNTech SE $4,018.00 07/14/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013021
Principal investigator 1 BioNTech SE $4,030.00 07/14/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013023
Principal investigator 1 BioNTech SE $440.00 07/14/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013025
Principal investigator 1 BioNTech SE $129.00 07/14/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249013027
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 07/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804552
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 07/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804554
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 07/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804556
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 07/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804558
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 07/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804560
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 07/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804562
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 07/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804564
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 07/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804566
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 07/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804568
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $525,106.00 07/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805039
Principal investigator 1 Daiichi Sankyo Inc. $304.00 07/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388561
Principal investigator 1 Daiichi Sankyo Inc. $304.00 07/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388563
Principal investigator 1 Daiichi Sankyo Inc. $135.00 07/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389621
Principal investigator 1 Daiichi Sankyo Inc. $540.00 07/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389623
Principal investigator 1 Daiichi Sankyo Inc. $61.00 07/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389625
Principal investigator 1 Daiichi Sankyo Inc. $81.00 07/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389627
Principal investigator 1 Daiichi Sankyo Inc. $332.00 07/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389629
Principal investigator 1 Daiichi Sankyo Inc. $205.00 07/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389685
Principal investigator 1 Daiichi Sankyo Inc. $405.00 07/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389751
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $121,500.00 07/12/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805429
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $101,250.00 07/12/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805431
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,508.88 07/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804546
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $29,000.00 07/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804548
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,384.15 07/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804550
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $71,478.00 07/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805389
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $65,225.70 07/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805391
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,580.00 07/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805393
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $917.00 07/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805395
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,727.40 07/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805397
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,505.63 07/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805399
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,066.95 07/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805401
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,424.50 07/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805403
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $187.00 07/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805405
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,587.60 07/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805407
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $457.50 07/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805409
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,476.50 07/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805411
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,500.00 07/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805413
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,947.00 07/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805415
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,000.00 07/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805417
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,973.75 07/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805419
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,973.75 07/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805421
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,973.75 07/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805423
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,616.99 07/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805425
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 07/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805427
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $598.00 07/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805693
Principal investigator 1 ABBVIE INC. $14,623.00 07/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202497900
Principal investigator 1 BioNTech SE $10,876.55 07/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-01 No dispute reported 06/30/2026 1249012829
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,384.15 07/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804544
Principal investigator 1 Daiichi Sankyo Inc. $18.25 07/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389607
Principal investigator 1 Daiichi Sankyo Inc. $46.50 07/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389731
Principal investigator 1 Daiichi Sankyo Inc. $20.85 07/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389733
Principal investigator 1 Genentech, Inc. $17,392.00 07/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Optimization of the CRS Profile for Glofit+GemOx in R/R DLBCL No dispute reported 06/30/2026 1211681948
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,752.54 07/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184214290
Principal investigator 1 BeOne Medicines Ltd. $47,160.00 07/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190336958
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,709.55 07/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804536
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,709.55 07/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804538
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,384.15 07/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804540
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,709.55 07/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804542
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $272.00 07/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804869
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $100.00 07/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804871
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,600.00 07/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804873
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,600.00 07/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804875
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,758.00 07/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804877
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,600.00 07/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804879
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,758.00 07/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804881
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,758.00 07/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804883
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,600.00 07/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804885
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,600.00 07/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804887
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,758.00 07/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804889
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,600.00 07/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804891
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,758.00 07/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804893
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,758.00 07/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804895
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,600.00 07/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804897
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,600.00 07/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804899
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $40,500.00 07/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805387
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $382.44 07/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805359
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $671.64 07/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805361
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,355.07 07/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805363
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,474.98 07/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805365
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,562.73 07/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805367
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $720.25 07/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805369
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $685.68 07/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805371
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $370.68 07/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805373
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,559.68 07/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805375
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,775.25 07/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805377
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,625.75 07/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805379
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,353.63 07/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805381
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $588.28 07/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805383
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,800.00 07/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805385
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 07/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804532
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 07/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804534
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34,168.50 07/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805691
Principal investigator 1 Janssen Research & Development, LLC $20,560.00 07/04/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413692
Principal investigator 1 Janssen Research & Development, LLC $20,560.00 07/04/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413748
Principal investigator 1 Janssen Research & Development, LLC $20,560.00 07/04/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413886
Principal investigator 1 Janssen Research & Development, LLC $20,560.00 07/04/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413997
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,207.80 07/04/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184212737
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $611.55 07/04/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184212739
Principal investigator 1 ABBVIE INC. $10,573.14 07/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202495117
Principal investigator 1 ABBVIE INC. $79,629.75 07/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202496019
Principal investigator 1 ABBVIE INC. $10,783.80 07/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202496021
Principal investigator 1 ABBVIE INC. $45,851.42 07/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-4) No dispute reported 06/30/2026 1202496023
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,694.00 07/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804867
Principal investigator 1 Daiichi Sankyo Inc. $2,004.00 07/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388559
Principal investigator 1 Daiichi Sankyo Inc. $20.00 07/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388575
Principal investigator 1 Daiichi Sankyo Inc. $6,615.00 07/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388577
Principal investigator 1 Daiichi Sankyo Inc. $5,172.00 07/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388595
Principal investigator 1 Daiichi Sankyo Inc. $346.00 07/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388597
Principal investigator 1 Daiichi Sankyo Inc. $2,763.00 07/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388599
Principal investigator 1 Daiichi Sankyo Inc. $84.00 07/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388601
Principal investigator 1 Daiichi Sankyo Inc. $2,763.00 07/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388603
Principal investigator 1 Daiichi Sankyo Inc. $279.00 07/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388605
Principal investigator 1 Daiichi Sankyo Inc. $435.00 07/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388607
Principal investigator 1 Daiichi Sankyo Inc. $5,153.00 07/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388609
Principal investigator 1 Daiichi Sankyo Inc. $6,091.00 07/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388611
Principal investigator 1 Daiichi Sankyo Inc. $62.00 07/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388639
Principal investigator 1 Daiichi Sankyo Inc. $6,853.00 07/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223388643
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 07/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577724
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 07/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577726
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704041
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220704175
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220704177
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 07/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220704179
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,097.80 07/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804851
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,059.00 07/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804853
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,500.00 07/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804855
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $15,489.00 07/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804857
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $17,475.00 07/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804859
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,694.00 07/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804861
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,059.00 07/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804863
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,694.00 07/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804865
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14,810.00 07/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805037
Principal investigator 1 Genentech, Inc. $28,000.00 07/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Optimization of the CRS Profile for Glofit+GemOx in R/R DLBCL No dispute reported 06/30/2026 1211681944
Principal investigator 1 Boehringer Ingelheim International GmbH $2,130.65 06/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704219
Principal investigator 1 Boehringer Ingelheim International GmbH $2,789.45 06/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704221
Principal investigator 1 Boehringer Ingelheim International GmbH $3,810.55 06/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704223
Principal investigator 1 Boehringer Ingelheim International GmbH $2,841.60 06/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704225
Principal investigator 1 Boehringer Ingelheim International GmbH $5,417.09 06/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704227
Principal investigator 1 Boehringer Ingelheim International GmbH $3,320.05 06/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704229
Principal investigator 1 Boehringer Ingelheim International GmbH $5,641.66 06/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704231
Principal investigator 1 Boehringer Ingelheim International GmbH $8,559.00 06/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704233
Principal investigator 1 Boehringer Ingelheim International GmbH $3,291.95 06/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704235
Principal investigator 1 Boehringer Ingelheim International GmbH $5,515.61 06/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704237
Principal investigator 1 Boehringer Ingelheim International GmbH $6,507.37 06/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704239
Principal investigator 1 Boehringer Ingelheim International GmbH $2,638.05 06/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704241
Principal investigator 1 Boehringer Ingelheim International GmbH $2,789.45 06/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704243
Principal investigator 1 Boehringer Ingelheim International GmbH $2,353.05 06/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704245
Principal investigator 1 Boehringer Ingelheim International GmbH $3,891.15 06/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704247
Principal investigator 1 Boehringer Ingelheim International GmbH $6,750.00 06/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704249
Principal investigator 1 Boehringer Ingelheim International GmbH $6,425.48 06/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704251
Principal investigator 1 Boehringer Ingelheim International GmbH $5,966.90 06/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704253
Principal investigator 1 Boehringer Ingelheim International GmbH $4,227.14 06/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704255
Principal investigator 1 Boehringer Ingelheim International GmbH $3,898.00 06/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704257
Principal investigator 1 Boehringer Ingelheim International GmbH $133.41 06/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704409
Principal investigator 1 Boehringer Ingelheim International GmbH $133.41 06/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704411
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 06/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805021
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 06/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805023
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 06/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805025
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 06/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805027
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 06/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805029
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $276.11 06/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805031
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $16.28 06/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805033
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,291.30 06/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805035
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,250.00 06/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220804530
Principal investigator 1 Genentech, Inc. $64,528.10 06/25/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211681960
Principal investigator 1 Boehringer Ingelheim International GmbH $509.10 06/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704023
Principal investigator 1 Boehringer Ingelheim International GmbH $139.92 06/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704025
Principal investigator 1 Boehringer Ingelheim International GmbH $539.46 06/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704027
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 06/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704029
Principal investigator 1 Boehringer Ingelheim International GmbH $244.28 06/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704031
Principal investigator 1 Boehringer Ingelheim International GmbH $143.00 06/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704033
Principal investigator 1 Boehringer Ingelheim International GmbH $30.66 06/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704035
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $586.00 06/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220996752
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $399.60 06/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220996754
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $303.16 06/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220996794
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $579.42 06/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220996796
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $584.00 06/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220996798
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $13.30 06/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220996800
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $7.10 06/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220996802
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $5.52 06/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220996804
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1.55 06/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220996806
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,525.14 06/24/2025 Non-covered Recipient Entity
Valkyrie Global, Inc
A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physicians Choice in Patients with Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC who are Ineligible for Anti-PD1/PD-L1 Treatment No dispute reported 06/30/2026 1235992021
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,274.12 06/24/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184210568
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,306.00 06/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804849
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $667.19 06/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805357
Principal investigator 1 Daiichi Sankyo Inc. $3,971.00 06/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389481
Principal investigator 1 Daiichi Sankyo Inc. $4,064.00 06/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389483
Principal investigator 1 Daiichi Sankyo Inc. $4,455.00 06/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389591
Principal investigator 1 Incyte Corporation $3,040.00 06/18/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240610791
Principal investigator 1 Incyte Corporation $2,822.00 06/18/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240610795
Principal investigator 1 Incyte Corporation $2,068.00 06/18/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240610807
Principal investigator 1 Incyte Corporation $2,916.00 06/18/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240610815
Principal investigator 1 BeOne Medicines Ltd. $13,677.00 06/17/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190331751
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $225.00 06/17/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804847
Principal investigator 1 ABBVIE INC. $858.83 06/13/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202491421
Principal investigator 1 Daiichi Sankyo Inc. $641.00 06/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388951
Principal investigator 1 Daiichi Sankyo Inc. $236.00 06/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388953
Principal investigator 1 Daiichi Sankyo Inc. $78.00 06/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388955
Principal investigator 1 Daiichi Sankyo Inc. $135.00 06/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388957
Principal investigator 1 Janssen Research & Development, LLC $20,560.00 06/13/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413834
Principal investigator 1 ABBVIE INC. $12,825.00 06/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202491197
Principal investigator 1 BeOne Medicines Ltd. $62,880.00 06/12/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190337002
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 06/12/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805003
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 06/12/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805005
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 06/12/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805007
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 06/12/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805009
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $719.26 06/12/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805011
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $347.58 06/12/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805013
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $807.46 06/12/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805015
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $928.16 06/12/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805017
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $820.23 06/12/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805019
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,752.54 06/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184206103
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $495.45 06/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184206105
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.25 06/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184206107
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,075.00 06/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184206109
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,075.00 06/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184206111
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,075.00 06/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184206113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,545.75 06/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184206115
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,075.00 06/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184206117
Principal investigator 1 ABBVIE INC. $29,243.70 06/11/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202490829
Principal investigator 1 ABBVIE INC. $25,650.00 06/11/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202490865
Principal investigator 1 ABBVIE INC. $12,825.00 06/11/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202490867
Principal investigator 1 Daiichi Sankyo Inc. $32.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389369
Principal investigator 1 Daiichi Sankyo Inc. $154.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389411
Principal investigator 1 Daiichi Sankyo Inc. $32.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389413
Principal investigator 1 Daiichi Sankyo Inc. $135.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389415
Principal investigator 1 Daiichi Sankyo Inc. $300.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389417
Principal investigator 1 Daiichi Sankyo Inc. $32.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389419
Principal investigator 1 Daiichi Sankyo Inc. $54.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389421
Principal investigator 1 Daiichi Sankyo Inc. $55.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389423
Principal investigator 1 Daiichi Sankyo Inc. $300.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389425
Principal investigator 1 Daiichi Sankyo Inc. $263.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389503
Principal investigator 1 Daiichi Sankyo Inc. $135.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389505
Principal investigator 1 Daiichi Sankyo Inc. $84.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389507
Principal investigator 1 Daiichi Sankyo Inc. $55.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389509
Principal investigator 1 Daiichi Sankyo Inc. $105.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389511
Principal investigator 1 Daiichi Sankyo Inc. $205.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389513
Principal investigator 1 Daiichi Sankyo Inc. $81.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389515
Principal investigator 1 Daiichi Sankyo Inc. $72.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389517
Principal investigator 1 Daiichi Sankyo Inc. $405.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389519
Principal investigator 1 Daiichi Sankyo Inc. $58.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389521
Principal investigator 1 Daiichi Sankyo Inc. $675.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389523
Principal investigator 1 Daiichi Sankyo Inc. $115.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389525
Principal investigator 1 Daiichi Sankyo Inc. $54.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389527
Principal investigator 1 Daiichi Sankyo Inc. $42.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389529
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389531
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389533
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389535
Principal investigator 1 Daiichi Sankyo Inc. $379.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389537
Principal investigator 1 Daiichi Sankyo Inc. $6,818.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389539
Principal investigator 1 Daiichi Sankyo Inc. $135.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389541
Principal investigator 1 Daiichi Sankyo Inc. $61.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389543
Principal investigator 1 Daiichi Sankyo Inc. $100.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389545
Principal investigator 1 Daiichi Sankyo Inc. $1,013.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389547
Principal investigator 1 Daiichi Sankyo Inc. $57.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389549
Principal investigator 1 Daiichi Sankyo Inc. $2,801.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389551
Principal investigator 1 Daiichi Sankyo Inc. $2,059.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389571
Principal investigator 1 Daiichi Sankyo Inc. $4,818.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389583
Principal investigator 1 Daiichi Sankyo Inc. $135.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389587
Principal investigator 1 Daiichi Sankyo Inc. $4,818.00 06/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389603
Principal investigator 1 Boehringer Ingelheim International GmbH $751.82 06/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703999
Principal investigator 1 Boehringer Ingelheim International GmbH $776.22 06/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704001
Principal investigator 1 Boehringer Ingelheim International GmbH $811.08 06/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704003
Principal investigator 1 Boehringer Ingelheim International GmbH $1,123.24 06/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704005
Principal investigator 1 Boehringer Ingelheim International GmbH $752.25 06/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704007
Principal investigator 1 Boehringer Ingelheim International GmbH $101.35 06/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704009
Principal investigator 1 Boehringer Ingelheim International GmbH $52.97 06/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704011
Principal investigator 1 Boehringer Ingelheim International GmbH $47.30 06/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704013
Principal investigator 1 Daiichi Sankyo Inc. $135.00 06/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389331
Principal investigator 1 Daiichi Sankyo Inc. $135.00 06/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389333
Principal investigator 1 Daiichi Sankyo Inc. $270.00 06/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389341
Principal investigator 1 Incyte Corporation $263.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240610802
Principal investigator 1 Incyte Corporation $2,708.10 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610811
Principal investigator 1 Incyte Corporation $61.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610820
Principal investigator 1 Incyte Corporation $675.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610824
Principal investigator 1 Incyte Corporation $2,709.05 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610829
Principal investigator 1 Incyte Corporation $2,822.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610832
Principal investigator 1 Incyte Corporation $77.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610836
Principal investigator 1 Incyte Corporation $196.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610840
Principal investigator 1 Incyte Corporation $101.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610843
Principal investigator 1 Incyte Corporation $506.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610846
Principal investigator 1 Incyte Corporation $603.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610850
Principal investigator 1 Incyte Corporation $2,916.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610854
Principal investigator 1 Incyte Corporation $196.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610859
Principal investigator 1 Incyte Corporation $1,806.03 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610863
Principal investigator 1 Incyte Corporation $101.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610867
Principal investigator 1 Incyte Corporation $101.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610869
Principal investigator 1 Incyte Corporation $3,040.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610873
Principal investigator 1 Incyte Corporation $603.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610877
Principal investigator 1 Incyte Corporation $263.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610880
Principal investigator 1 Incyte Corporation $2,822.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610883
Principal investigator 1 Incyte Corporation $77.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610886
Principal investigator 1 Incyte Corporation $196.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610889
Principal investigator 1 Incyte Corporation $603.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610897
Principal investigator 1 Incyte Corporation $603.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610900
Principal investigator 1 Incyte Corporation $603.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610904
Principal investigator 1 Incyte Corporation $2,822.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610907
Principal investigator 1 Incyte Corporation $55.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610912
Principal investigator 1 Incyte Corporation $95.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610919
Principal investigator 1 Incyte Corporation $129.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610923
Principal investigator 1 Incyte Corporation $129.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610927
Principal investigator 1 Incyte Corporation $3,040.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610939
Principal investigator 1 Incyte Corporation $2,709.05 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610942
Principal investigator 1 Incyte Corporation $603.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610949
Principal investigator 1 Incyte Corporation $2,916.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610961
Principal investigator 1 Incyte Corporation $196.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610965
Principal investigator 1 Incyte Corporation $196.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610968
Principal investigator 1 Incyte Corporation $196.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610972
Principal investigator 1 Incyte Corporation $101.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610993
Principal investigator 1 Incyte Corporation $101.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610997
Principal investigator 1 Incyte Corporation $101.00 06/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240611000
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $145.33 06/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220804999
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $430.10 06/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220805001
Principal investigator 1 Boehringer Ingelheim International GmbH $112.00 06/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704015
Principal investigator 1 Boehringer Ingelheim International GmbH $242.00 06/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704017
Principal investigator 1 ABBVIE INC. $6,031.46 06/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202488519
Principal investigator 1 ABBVIE INC. $76,893.30 06/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202489333
Principal investigator 1 Janssen Research & Development, LLC $20,560.00 06/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413730
Principal investigator 1 BeOne Medicines Ltd. $31,440.00 06/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190330395
Principal investigator 1 Daiichi Sankyo Inc. $416.00 06/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389111
Principal investigator 1 Daiichi Sankyo Inc. $263.00 06/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389389
Principal investigator 1 Daiichi Sankyo Inc. $405.00 06/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389391
Principal investigator 1 Daiichi Sankyo Inc. $81.00 06/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389601
Principal investigator 1 Janssen Research & Development, LLC $20,560.00 06/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413754
Principal investigator 1 Janssen Research & Development, LLC $20,560.00 06/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413791
Principal investigator 1 Janssen Research & Development, LLC $20,560.00 06/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413803
Principal investigator 1 Janssen Research & Development, LLC $20,560.00 06/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413870
Principal investigator 1 Janssen Research & Development, LLC $20,560.00 06/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413897
Principal investigator 1 Janssen Research & Development, LLC $20,560.00 06/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413922
Principal investigator 1 Janssen Research & Development, LLC $7,020.00 06/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413935
Principal investigator 1 Janssen Research & Development, LLC $20,560.00 06/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413976
Principal investigator 1 Janssen Research & Development, LLC $20,560.00 06/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175414007
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 06/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577720
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 06/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577722
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703997
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 06/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220704167
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 06/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220704169
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220704171
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220704173
Principal investigator 1 Boehringer Ingelheim International GmbH $133.41 05/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704405
Principal investigator 1 Boehringer Ingelheim International GmbH $133.41 05/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704407
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $835.89 05/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805683
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,037.75 05/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805685
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $740.02 05/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805687
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $660.02 05/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805689
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,892.95 05/29/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804845
Principal investigator 1 Genentech, Inc. $42,181.00 05/28/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211681962
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,191.85 05/28/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184198803
Principal investigator 1 ABBVIE INC. $12,825.00 05/27/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202486201
Principal investigator 1 ABBVIE INC. $25,650.00 05/27/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202486203
Principal investigator 1 ABBVIE INC. $25,650.00 05/27/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202486205
Principal investigator 1 ABBVIE INC. $38,475.00 05/27/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202486207
Principal investigator 1 ABBVIE INC. $14,623.00 05/27/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202486209
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 05/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704019
Principal investigator 1 Boehringer Ingelheim International GmbH $4.00 05/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220704021
Principal investigator 1 Boehringer Ingelheim International GmbH $178.90 05/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704413
Principal investigator 1 Boehringer Ingelheim International GmbH $1,131.02 05/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704415
Principal investigator 1 Boehringer Ingelheim International GmbH $459.54 05/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704417
Principal investigator 1 Boehringer Ingelheim International GmbH $839.50 05/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704419
Principal investigator 1 Boehringer Ingelheim International GmbH $56.50 05/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704421
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $139.92 05/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220996760
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $199.80 05/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220996762
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $401.50 05/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220996764
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $732.84 05/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220996766
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $97.20 05/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220996768
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $686.98 05/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220996770
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,826.07 05/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805681
Principal investigator 1 Daiichi Sankyo Inc. $358.34 05/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389025
Principal investigator 1 Daiichi Sankyo Inc. $518.09 05/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389027
Principal investigator 1 Daiichi Sankyo Inc. $135.00 05/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389557
Principal investigator 1 Daiichi Sankyo Inc. $32.00 05/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389559
Principal investigator 1 Daiichi Sankyo Inc. $97.00 05/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389561
Principal investigator 1 Daiichi Sankyo Inc. $115.00 05/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389593
Principal investigator 1 Boehringer Ingelheim International GmbH $3,510.00 05/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703973
Principal investigator 1 Boehringer Ingelheim International GmbH $3,105.00 05/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703975
Principal investigator 1 Boehringer Ingelheim International GmbH $3,105.00 05/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703977
Principal investigator 1 Boehringer Ingelheim International GmbH $989.00 05/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703979
Principal investigator 1 Boehringer Ingelheim International GmbH $473.00 05/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703981
Principal investigator 1 Boehringer Ingelheim International GmbH $5,306.00 05/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703983
Principal investigator 1 Boehringer Ingelheim International GmbH $3,510.00 05/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703985
Principal investigator 1 Boehringer Ingelheim International GmbH $3,105.00 05/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703987
Principal investigator 1 Boehringer Ingelheim International GmbH $3,105.00 05/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703989
Principal investigator 1 Boehringer Ingelheim International GmbH $258.00 05/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703991
Principal investigator 1 Boehringer Ingelheim International GmbH $989.00 05/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703993
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $33.58 05/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804839
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $399.82 05/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804841
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $153.36 05/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804843
Principal investigator 1 BeiGene, Ltd. $4,301.00 05/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190320412
Principal investigator 1 BeiGene, Ltd. $12,114.12 05/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190320976
Principal investigator 1 BeiGene, Ltd. $279.00 05/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190320980
Principal investigator 1 BeiGene, Ltd. $1,518.00 05/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190320982
Principal investigator 1 BeiGene, Ltd. $198.00 05/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190320984
Principal investigator 1 BeiGene, Ltd. $11,454.12 05/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190320986
Principal investigator 1 BeiGene, Ltd. $1,154.08 05/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190320988
Principal investigator 1 BeiGene, Ltd. $14,976.72 05/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190320990
Principal investigator 1 BeiGene, Ltd. $198.00 05/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190320996
Principal investigator 1 BeiGene, Ltd. $16,587.12 05/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190320998
Principal investigator 1 BeiGene, Ltd. $1,518.00 05/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190321000
Principal investigator 1 BeiGene, Ltd. $9,900.00 05/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190321002
Principal investigator 1 BeiGene, Ltd. $279.00 05/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190321008
Principal investigator 1 BeiGene, Ltd. $1,518.00 05/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190321012
Principal investigator 1 BeiGene, Ltd. $7,206.24 05/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190321014
Principal investigator 1 BeiGene, Ltd. $2,383.08 05/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190321018
Principal investigator 1 BeiGene, Ltd. $12,114.12 05/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190321020
Principal investigator 1 BeiGene, Ltd. $14,976.72 05/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190321022
Principal investigator 1 BeiGene, Ltd. $11,373.12 05/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190321024
Principal investigator 1 BeiGene, Ltd. $11,677.00 05/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190325664
Principal investigator 1 BioNTech SE $5,571.00 05/19/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012749
Principal investigator 1 BioNTech SE $135.00 05/19/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012751
Principal investigator 1 BioNTech SE $405.00 05/19/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012753
Principal investigator 1 BioNTech SE $405.00 05/19/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012755
Principal investigator 1 BioNTech SE $405.00 05/19/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012757
Principal investigator 1 BioNTech SE $77.00 05/19/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012759
Principal investigator 1 BioNTech SE $405.00 05/19/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012761
Principal investigator 1 BioNTech SE $101.00 05/19/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012763
Principal investigator 1 BioNTech SE $135.00 05/19/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012983
Principal investigator 1 BioNTech SE $5,571.00 05/19/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012985
Principal investigator 1 BioNTech SE $5,301.00 05/19/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012987
Principal investigator 1 BioNTech SE $405.00 05/19/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012993
Principal investigator 1 BioNTech SE $77.00 05/19/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012995
Principal investigator 1 BioNTech SE $101.00 05/19/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012997
Principal investigator 1 BioNTech SE $154.00 05/19/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012999
Principal investigator 1 Daiichi Sankyo Inc. $135.00 05/19/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389553
Principal investigator 1 Daiichi Sankyo Inc. $81.00 05/19/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389555
Principal investigator 1 Daiichi Sankyo Inc. $32.00 05/19/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389575
Principal investigator 1 Incyte Corporation $4,836.00 05/19/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610765
Principal investigator 1 Incyte Corporation $2,822.00 05/19/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610769
Principal investigator 1 Incyte Corporation $258.00 05/19/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610777
Principal investigator 1 Incyte Corporation $675.00 05/19/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610788
Principal investigator 1 Incyte Corporation $3,040.00 05/19/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610798
Principal investigator 1 Incyte Corporation $2,916.00 05/19/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610977
Principal investigator 1 BeiGene, Ltd. $31,440.00 05/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323548
Principal investigator 1 Daiichi Sankyo Inc. $1,328.00 05/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389311
Principal investigator 1 Daiichi Sankyo Inc. $2,950.00 05/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389313
Principal investigator 1 Daiichi Sankyo Inc. $5,210.00 05/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389315
Principal investigator 1 Daiichi Sankyo Inc. $2,898.00 05/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389317
Principal investigator 1 Daiichi Sankyo Inc. $4,807.00 05/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389319
Principal investigator 1 Daiichi Sankyo Inc. $2,898.00 05/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389321
Principal investigator 1 Daiichi Sankyo Inc. $5,578.00 05/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389323
Principal investigator 1 Daiichi Sankyo Inc. $2,898.00 05/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389325
Principal investigator 1 Daiichi Sankyo Inc. $5,210.00 05/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389327
Principal investigator 1 Daiichi Sankyo Inc. $6,055.00 05/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389329
Principal investigator 1 Daiichi Sankyo Inc. $2,898.00 05/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389335
Principal investigator 1 Daiichi Sankyo Inc. $6,148.00 05/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389337
Principal investigator 1 Daiichi Sankyo Inc. $304.00 05/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389339
Principal investigator 1 Daiichi Sankyo Inc. $5,719.00 05/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389343
Principal investigator 1 Genentech, Inc. $156,735.00 05/14/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211681968
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $30,655.80 05/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805679
Principal investigator 1 Janssen Research & Development, LLC $149,822.00 05/08/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413970
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,752.54 05/08/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184193695
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,062.50 05/08/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184193697
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20,629.35 05/08/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184193699
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,315.05 05/08/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184193701
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,692.05 05/08/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184193703
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,375.00 05/08/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184193705
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,201.05 05/08/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184193707
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,819.35 05/08/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184193709
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,872.50 05/08/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184193711
Principal investigator 1 ABBVIE INC. $6,100.92 05/07/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202482873
Principal investigator 1 ABBVIE INC. $92,298.15 05/07/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202482875
Principal investigator 1 ABBVIE INC. $37,125.00 05/07/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202482927
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389371
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389373
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389375
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389377
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389379
Principal investigator 1 Daiichi Sankyo Inc. $379.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389381
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389383
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389385
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389387
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389393
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389395
Principal investigator 1 Daiichi Sankyo Inc. $3,784.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389397
Principal investigator 1 Daiichi Sankyo Inc. $6,404.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389399
Principal investigator 1 Daiichi Sankyo Inc. $6,404.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389401
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389403
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389405
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389407
Principal investigator 1 Daiichi Sankyo Inc. $6,818.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389409
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389431
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389435
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389437
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389439
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389445
Principal investigator 1 Daiichi Sankyo Inc. $4,455.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389447
Principal investigator 1 Daiichi Sankyo Inc. $6,818.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389449
Principal investigator 1 Daiichi Sankyo Inc. $6,278.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389451
Principal investigator 1 Daiichi Sankyo Inc. $2,801.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389453
Principal investigator 1 Daiichi Sankyo Inc. $379.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389455
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389457
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389459
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389461
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389463
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389465
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389467
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389469
Principal investigator 1 Daiichi Sankyo Inc. $42.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389471
Principal investigator 1 Daiichi Sankyo Inc. $405.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389473
Principal investigator 1 Daiichi Sankyo Inc. $263.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389475
Principal investigator 1 Daiichi Sankyo Inc. $300.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389477
Principal investigator 1 Daiichi Sankyo Inc. $81.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389479
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389485
Principal investigator 1 Daiichi Sankyo Inc. $379.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389487
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389489
Principal investigator 1 Daiichi Sankyo Inc. $4,064.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389491
Principal investigator 1 Daiichi Sankyo Inc. $4,455.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389493
Principal investigator 1 Daiichi Sankyo Inc. $3,971.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389495
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389497
Principal investigator 1 Daiichi Sankyo Inc. $32.40 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389499
Principal investigator 1 Daiichi Sankyo Inc. $135.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389501
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389563
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389565
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389567
Principal investigator 1 Daiichi Sankyo Inc. $6,818.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389569
Principal investigator 1 Daiichi Sankyo Inc. $270.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389573
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389577
Principal investigator 1 Daiichi Sankyo Inc. $2,801.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389579
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389581
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389585
Principal investigator 1 Daiichi Sankyo Inc. $135.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389589
Principal investigator 1 Daiichi Sankyo Inc. $6,404.00 05/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389595
Principal investigator 1 Incyte Corporation $1,378.45 05/07/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240610934
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $80,496.90 05/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805355
Principal investigator 1 Boehringer Ingelheim International GmbH $12,164.00 05/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703937
Principal investigator 1 Boehringer Ingelheim International GmbH $7,946.00 05/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703939
Principal investigator 1 Boehringer Ingelheim International GmbH $7,946.00 05/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703941
Principal investigator 1 Boehringer Ingelheim International GmbH $790.00 05/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703943
Principal investigator 1 Boehringer Ingelheim International GmbH $790.00 05/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703945
Principal investigator 1 Boehringer Ingelheim International GmbH $355.00 05/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703947
Principal investigator 1 Boehringer Ingelheim International GmbH $12,164.00 05/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703949
Principal investigator 1 Boehringer Ingelheim International GmbH $145.00 05/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703951
Principal investigator 1 Boehringer Ingelheim International GmbH $145.00 05/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703953
Principal investigator 1 Boehringer Ingelheim International GmbH $145.00 05/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703955
Principal investigator 1 Boehringer Ingelheim International GmbH $145.00 05/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703957
Principal investigator 1 Boehringer Ingelheim International GmbH $47.00 05/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703959
Principal investigator 1 Boehringer Ingelheim International GmbH $355.00 05/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703961
Principal investigator 1 Boehringer Ingelheim International GmbH $3,510.00 05/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703963
Principal investigator 1 Boehringer Ingelheim International GmbH $3,105.00 05/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703965
Principal investigator 1 Boehringer Ingelheim International GmbH $190.00 05/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703967
Principal investigator 1 Boehringer Ingelheim International GmbH $989.00 05/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703969
Principal investigator 1 Boehringer Ingelheim International GmbH $3,105.00 05/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703971
Principal investigator 1 Daiichi Sankyo Inc. $6,384.00 05/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388943
Principal investigator 1 Daiichi Sankyo Inc. $6,249.00 05/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388945
Principal investigator 1 Daiichi Sankyo Inc. $6,384.00 05/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388947
Principal investigator 1 Daiichi Sankyo Inc. $2,557.00 05/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388949
Principal investigator 1 Daiichi Sankyo Inc. $675.00 05/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388959
Principal investigator 1 Daiichi Sankyo Inc. $294.29 05/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388961
Principal investigator 1 Daiichi Sankyo Inc. $1,418.00 05/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $675.00 05/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184191877
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,144.35 05/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184191879
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,375.00 05/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184191881
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,169.25 05/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184191883
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,201.05 05/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184191885
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,819.35 05/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184191887
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,819.35 05/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184191889
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,819.35 05/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184191891
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,819.35 05/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184192071
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,819.35 05/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184192073
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,080.00 05/02/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184192075
Principal investigator 1 BioNTech SE $97.00 05/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012841
Principal investigator 1 BioNTech SE $97.00 05/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012843
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 05/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577716
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 05/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577718
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703995
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220704163
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220704165
Principal investigator 1 Boehringer Ingelheim International GmbH $785.00 05/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220704369
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $29,690.35 05/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804837
Principal investigator 1 BeiGene, Ltd. $31,440.00 04/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325228
Principal investigator 1 Boehringer Ingelheim International GmbH $1,370.21 04/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220704371
Principal investigator 1 Boehringer Ingelheim International GmbH $1.94 04/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220704373
Principal investigator 1 Boehringer Ingelheim International GmbH $133.41 04/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704397
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,284.19 04/28/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184190613
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 04/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220804997
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $81.62 04/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220996786
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $59.94 04/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220996788
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $146.00 04/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220996790
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $2.76 04/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220996792
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20.00 04/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220804993
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,055.50 04/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220804995
Principal investigator 1 BeiGene, Ltd. $6,222.00 04/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190320416
Principal investigator 1 Boehringer Ingelheim International GmbH $36.02 04/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704399
Principal investigator 1 BioNTech SE $3,147.45 04/21/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012989
Principal investigator 1 BioNTech SE $3,456.00 04/21/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT321-02 No dispute reported 06/30/2026 1249012991
Principal investigator 1 ABBVIE INC. $26,611.20 04/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202477324
Principal investigator 1 BeiGene, Ltd. $13,602.00 04/17/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190320414
Principal investigator 1 BeiGene, Ltd. $8,831.00 04/17/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190325658
Principal investigator 1 BeiGene, Ltd. $31,440.00 04/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190322242
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,239.00 04/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805677
Principal investigator 1 BeiGene, Ltd. $15,720.00 04/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321962
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $51,142.50 04/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805675
Principal investigator 1 BeiGene, Ltd. $47,160.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321864
Principal investigator 1 BeiGene, Ltd. $15,720.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190323888
Principal investigator 1 Daiichi Sankyo Inc. $3,015.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388941
Principal investigator 1 Daiichi Sankyo Inc. $4,368.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388963
Principal investigator 1 Daiichi Sankyo Inc. $6,818.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388965
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388967
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388969
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388971
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388973
Principal investigator 1 Daiichi Sankyo Inc. $6,818.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388975
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388977
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388979
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388981
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388983
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388985
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388987
Principal investigator 1 Daiichi Sankyo Inc. $6,818.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388989
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388991
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388993
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388995
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388997
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388999
Principal investigator 1 Daiichi Sankyo Inc. $6,818.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389001
Principal investigator 1 Daiichi Sankyo Inc. $6,818.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389003
Principal investigator 1 Daiichi Sankyo Inc. $6,818.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389005
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389007
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389009
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389011
Principal investigator 1 Daiichi Sankyo Inc. $6,818.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389013
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389015
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389017
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389019
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389021
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389023
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389029
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389031
Principal investigator 1 Daiichi Sankyo Inc. $6,818.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389033
Principal investigator 1 Daiichi Sankyo Inc. $6,818.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389035
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389037
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389039
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389041
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389043
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389045
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389047
Principal investigator 1 Daiichi Sankyo Inc. $6,818.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389049
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389051
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389053
Principal investigator 1 Daiichi Sankyo Inc. $6,818.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389055
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389057
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389059
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389061
Principal investigator 1 Daiichi Sankyo Inc. $6,818.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389063
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389065
Principal investigator 1 Daiichi Sankyo Inc. $6,818.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389067
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389069
Principal investigator 1 Daiichi Sankyo Inc. $2,970.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389071
Principal investigator 1 Daiichi Sankyo Inc. $2,970.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389073
Principal investigator 1 Daiichi Sankyo Inc. $5,468.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389075
Principal investigator 1 Daiichi Sankyo Inc. $5,397.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389077
Principal investigator 1 Daiichi Sankyo Inc. $2,970.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389079
Principal investigator 1 Daiichi Sankyo Inc. $1,418.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389081
Principal investigator 1 Daiichi Sankyo Inc. $3,980.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389083
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389085
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389087
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389089
Principal investigator 1 Daiichi Sankyo Inc. $6,818.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389091
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389093
Principal investigator 1 Daiichi Sankyo Inc. $6,818.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389097
Principal investigator 1 Daiichi Sankyo Inc. $8,500.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389099
Principal investigator 1 Daiichi Sankyo Inc. $6,818.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389101
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389103
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389105
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389107
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389109
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389113
Principal investigator 1 Daiichi Sankyo Inc. $4,818.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389427
Principal investigator 1 Daiichi Sankyo Inc. $4,818.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389429
Principal investigator 1 Daiichi Sankyo Inc. $6,404.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389433
Principal investigator 1 Daiichi Sankyo Inc. $4,818.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389597
Principal investigator 1 Daiichi Sankyo Inc. $4,818.00 04/09/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389599
Principal investigator 1 Incyte Corporation $750.00 04/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610747
Principal investigator 1 Incyte Corporation $695.00 04/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610751
Principal investigator 1 Incyte Corporation $1,750.00 04/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610755
Principal investigator 1 Incyte Corporation $660.00 04/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610761
Principal investigator 1 Incyte Corporation $4,000.00 04/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610772
Principal investigator 1 Incyte Corporation $695.00 04/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610780
Principal investigator 1 Incyte Corporation $110.00 04/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610893
Principal investigator 1 Incyte Corporation $3,300.00 04/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610931
Principal investigator 1 Incyte Corporation $2,000.00 04/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610945
Principal investigator 1 Incyte Corporation $110.00 04/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610953
Principal investigator 1 Incyte Corporation $110.00 04/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610958
Principal investigator 1 Incyte Corporation $695.00 04/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610981
Principal investigator 1 Incyte Corporation $660.00 04/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610985
Principal investigator 1 Incyte Corporation $660.00 04/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610989
Principal investigator 1 Boehringer Ingelheim International GmbH $20.53 04/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704401
Principal investigator 1 Boehringer Ingelheim International GmbH $7.18 04/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704403
Principal investigator 1 Incyte Corporation $140.10 04/07/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240610784
Principal investigator 1 Incyte Corporation $3,449.00 04/07/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240610916
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $27,065.62 04/04/2025 Non-covered Recipient Entity
Valkyrie Global, Inc
A Phase 1, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination with Chemotherapy or Nivolumab in Advanced Solid Tumors No dispute reported 06/30/2026 1235992015
Principal investigator 1 ABBVIE INC. $19,079.55 04/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202469704
Principal investigator 1 ABBVIE INC. $104,811.30 04/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202469708
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $16,990.75 04/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804825
Principal investigator 1 Boehringer Ingelheim International GmbH $5,000.00 04/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703935
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $10,010.43 04/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220996834
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $10,010.43 04/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220996836
Principal investigator 1 Daiichi Sankyo Inc. $7,290.00 04/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389303
Principal investigator 1 Daiichi Sankyo Inc. $6,210.00 04/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389305
Principal investigator 1 Daiichi Sankyo Inc. $6,075.00 04/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389307
Principal investigator 1 Daiichi Sankyo Inc. $5,332.50 04/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389309
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 04/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389367
Principal investigator 1 Daiichi Sankyo Inc. $4,143.00 04/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389441
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 04/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389443
Principal investigator 1 BeiGene, Ltd. $12,193.51 04/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190320978
Principal investigator 1 BeiGene, Ltd. $15,636.72 04/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190320992
Principal investigator 1 BeiGene, Ltd. $1,357.00 04/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190320994
Principal investigator 1 BeiGene, Ltd. $2,000.00 04/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190321004
Principal investigator 1 BeiGene, Ltd. $1,023.00 04/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190321006
Principal investigator 1 BeiGene, Ltd. $429.00 04/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190321010
Principal investigator 1 BeiGene, Ltd. $12,356.07 04/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190321016
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 04/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577712
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 04/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577714
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703933
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220704159
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220704161
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $719.55 04/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184180542
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,667.60 04/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184180546
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,065.00 04/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184180548
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,661.65 04/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184180766
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,939.57 04/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184180768
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 04/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184180772
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 04/01/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184180774
Principal investigator 1 Boehringer Ingelheim International GmbH $1,745.55 03/31/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704213
Principal investigator 1 Janssen Research & Development, LLC $83,790.00 03/31/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413679
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,265.95 03/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805349
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,973.80 03/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805351
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $16,872.97 03/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805353
Principal investigator 1 ABBVIE INC. $2,067.00 03/27/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
M24-287 - A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202466783
Principal investigator 1 Boehringer Ingelheim International GmbH $84.05 03/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
PhII in 2nd line pts with Her2+ tumors other than NSCLC No dispute reported 06/30/2026 1220704375
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $33,981.50 03/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804835
Principal investigator 1 ABBVIE INC. $3,367.00 03/26/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
M24-287 - A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202466188
Principal investigator 1 ABBVIE INC. $155.00 03/26/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
M24-287 - A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202466193
Principal investigator 1 ABBVIE INC. $1,163.00 03/26/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
M24-287 - A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202466197
Principal investigator 1 ABBVIE INC. $3,421.00 03/26/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
M24-287 - A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202466201
Principal investigator 1 ABBVIE INC. $221.40 03/26/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202466205
Principal investigator 1 Boehringer Ingelheim International GmbH $68.00 03/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703855
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 03/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703857
Principal investigator 1 Boehringer Ingelheim International GmbH $1,086.00 03/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703859
Principal investigator 1 Boehringer Ingelheim International GmbH $68.00 03/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703905
Principal investigator 1 Boehringer Ingelheim International GmbH $829.00 03/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703907
Principal investigator 1 Boehringer Ingelheim International GmbH $675.00 03/26/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703909
Principal investigator 1 Genentech, Inc. $83,059.80 03/26/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211681966
Principal investigator 1 BeOne Medicines USA, Inc. $612.00 03/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190338637
Principal investigator 1 BeOne Medicines USA, Inc. $612.00 03/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190338640
Principal investigator 1 BeiGene, Ltd. $11,896.00 03/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190325656
Principal investigator 1 Boehringer Ingelheim International GmbH $169.70 03/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703925
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 03/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703927
Principal investigator 1 Boehringer Ingelheim International GmbH $20.00 03/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703929
Principal investigator 1 Boehringer Ingelheim International GmbH $14.60 03/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703931
Principal investigator 1 Boehringer Ingelheim International GmbH $143.12 03/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704385
Principal investigator 1 Boehringer Ingelheim International GmbH $1,072.72 03/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704387
Principal investigator 1 Boehringer Ingelheim International GmbH $279.72 03/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704389
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 03/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704391
Principal investigator 1 Boehringer Ingelheim International GmbH $59.64 03/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704393
Principal investigator 1 Boehringer Ingelheim International GmbH $41.00 03/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704395
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $293.00 03/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220996744
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $466.40 03/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220996746
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $199.80 03/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220996748
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $53.20 03/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220996750
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $254.55 03/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220996808
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $209.88 03/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220996810
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $119.88 03/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220996812
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $73.00 03/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220996814
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $21.02 03/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220996816
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $16.80 03/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220996818
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $15.50 03/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220996820
Principal investigator 1 Incyte Corporation $2,250.00 03/24/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610676
Principal investigator 1 Daiichi Sankyo Inc. $3,240.00 03/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389115
Principal investigator 1 Daiichi Sankyo Inc. $135.00 03/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389117
Principal investigator 1 Daiichi Sankyo Inc. $2,801.00 03/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389119
Principal investigator 1 Daiichi Sankyo Inc. $57.92 03/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389121
Principal investigator 1 Daiichi Sankyo Inc. $185.00 03/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389123
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 03/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389125
Principal investigator 1 Daiichi Sankyo Inc. $6,818.00 03/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389127
Principal investigator 1 Daiichi Sankyo Inc. $2,801.00 03/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389129
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 03/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389131
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 03/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389133
Principal investigator 1 Daiichi Sankyo Inc. $379.00 03/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389135
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 03/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389137
Principal investigator 1 Daiichi Sankyo Inc. $4,187.55 03/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389139
Principal investigator 1 Daiichi Sankyo Inc. $6,818.00 03/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389141
Principal investigator 1 Daiichi Sankyo Inc. $379.00 03/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389143
Principal investigator 1 Daiichi Sankyo Inc. $379.00 03/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389147
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 03/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389149
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 03/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389151
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 03/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389153
Principal investigator 1 Daiichi Sankyo Inc. $6,818.00 03/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389155
Principal investigator 1 Daiichi Sankyo Inc. $177.00 03/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389207
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 03/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389211
Principal investigator 1 Daiichi Sankyo Inc. $2,801.00 03/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389213
Principal investigator 1 Daiichi Sankyo Inc. $641.00 03/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389215
Principal investigator 1 ABBVIE INC. $3,553.00 03/20/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
M24-287 - A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202465123
Principal investigator 1 Janssen Research & Development, LLC $56,969.00 03/20/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413949
Principal investigator 1 BeiGene, Ltd. $31,440.00 03/19/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321910
Principal investigator 1 BioNTech SE $8,467.35 03/19/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-01 No dispute reported 06/30/2026 1249012825
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,237.10 03/19/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805669
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $992.30 03/19/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805671
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $500.00 03/19/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805673
Principal investigator 1 Daiichi Sankyo Inc. $1,000.00 03/19/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389345
Principal investigator 1 Daiichi Sankyo Inc. $2,000.00 03/19/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389347
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 03/19/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389349
Principal investigator 1 Daiichi Sankyo Inc. $6,615.00 03/19/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389351
Principal investigator 1 Daiichi Sankyo Inc. $3,000.00 03/19/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389353
Principal investigator 1 Daiichi Sankyo Inc. $6,210.00 03/19/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389355
Principal investigator 1 Daiichi Sankyo Inc. $1,700.00 03/19/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389357
Principal investigator 1 Daiichi Sankyo Inc. $6,075.00 03/19/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389359
Principal investigator 1 Daiichi Sankyo Inc. $379.00 03/19/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389361
Principal investigator 1 Daiichi Sankyo Inc. $12,825.00 03/19/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389363
Principal investigator 1 Daiichi Sankyo Inc. $5,333.00 03/19/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389365
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20,737.34 03/19/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184174630
Principal investigator 1 Boehringer Ingelheim International GmbH $60.04 03/17/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704379
Principal investigator 1 Boehringer Ingelheim International GmbH $20.53 03/17/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704381
Principal investigator 1 Boehringer Ingelheim International GmbH $7.18 03/17/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220704383
Principal investigator 1 PFIZER INC. $15,338.70 03/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228859345
Principal investigator 1 BioNTech SE $3,402.90 03/14/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012939
Principal investigator 1 Boehringer Ingelheim International GmbH $203.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703901
Principal investigator 1 Boehringer Ingelheim International GmbH $68.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703903
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389841
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389843
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389845
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389847
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389849
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389851
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389853
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389855
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389857
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389859
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389861
Principal investigator 1 Daiichi Sankyo Inc. $135.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389863
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389865
Principal investigator 1 Daiichi Sankyo Inc. $42.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389867
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389869
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389871
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389873
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389875
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389877
Principal investigator 1 Daiichi Sankyo Inc. $6,211.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389879
Principal investigator 1 Daiichi Sankyo Inc. $6,193.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389881
Principal investigator 1 Daiichi Sankyo Inc. $5,410.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389883
Principal investigator 1 Daiichi Sankyo Inc. $379.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389885
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389887
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389889
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389891
Principal investigator 1 Daiichi Sankyo Inc. $2,943.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389955
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389957
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389959
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389961
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389963
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389965
Principal investigator 1 Daiichi Sankyo Inc. $6,818.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389967
Principal investigator 1 Daiichi Sankyo Inc. $2,801.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389969
Principal investigator 1 Daiichi Sankyo Inc. $405.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389973
Principal investigator 1 Daiichi Sankyo Inc. $270.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389975
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389977
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389987
Principal investigator 1 Daiichi Sankyo Inc. $6,818.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389989
Principal investigator 1 Daiichi Sankyo Inc. $978.00 03/14/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389991
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 03/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220804991
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $62,433.90 03/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805667
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $10,010.43 03/12/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220996832
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,333.06 03/12/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805663
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,333.06 03/12/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805665
Principal investigator 1 Daiichi Sankyo Inc. $4,818.00 03/12/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389911
Principal investigator 1 Daiichi Sankyo Inc. $4,818.00 03/12/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389913
Principal investigator 1 Daiichi Sankyo Inc. $4,818.00 03/12/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389915
Principal investigator 1 Daiichi Sankyo Inc. $4,818.00 03/12/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389917
Principal investigator 1 Daiichi Sankyo Inc. $4,818.00 03/12/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389919
Principal investigator 1 Incyte Corporation $547.00 03/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240610706
Principal investigator 1 Incyte Corporation $329.00 03/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240610725
Principal investigator 1 Incyte Corporation $329.00 03/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240610728
Principal investigator 1 Incyte Corporation $3,216.30 03/12/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240610739
Principal investigator 1 BeiGene, Ltd. $31,440.00 03/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190323862
Principal investigator 1 BioNTech SE $10,562.10 03/11/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-01 No dispute reported 06/30/2026 1249012823
Principal investigator 1 Novartis Pharmaceuticals Corporation $18,157.99 03/10/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination With Carboplatin, Etoposide and Tislelizumab in Induction and With Tislelizumab in Mainte No dispute reported 06/30/2026 1190312855
Principal investigator 1 ABBVIE INC. $25,057.15 03/07/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202460707
Principal investigator 1 ABBVIE INC. $51,767.10 03/07/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
M24-287 - A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202460709
Principal investigator 1 Daiichi Sankyo Inc. $195.60 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388845
Principal investigator 1 Daiichi Sankyo Inc. $126.80 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388847
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388849
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388851
Principal investigator 1 Daiichi Sankyo Inc. $250.75 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388853
Principal investigator 1 Daiichi Sankyo Inc. $618.60 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388855
Principal investigator 1 Daiichi Sankyo Inc. $293.25 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388857
Principal investigator 1 Daiichi Sankyo Inc. $78.00 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388859
Principal investigator 1 Daiichi Sankyo Inc. $112.05 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388867
Principal investigator 1 Daiichi Sankyo Inc. $62.55 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388869
Principal investigator 1 Daiichi Sankyo Inc. $62.55 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388871
Principal investigator 1 Daiichi Sankyo Inc. $62.55 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388873
Principal investigator 1 Daiichi Sankyo Inc. $62.55 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388875
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388877
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388879
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388881
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388883
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388885
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388887
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388889
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388891
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388893
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388895
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388897
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388899
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388901
Principal investigator 1 Daiichi Sankyo Inc. $166.60 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388909
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388911
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388913
Principal investigator 1 Daiichi Sankyo Inc. $112.05 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388915
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388917
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388921
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388923
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388933
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388937
Principal investigator 1 Amgen Inc. $241,288.09 03/05/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1246651091
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $394.00 03/05/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805661
Principal investigator 1 BioNTech SE $2,835.75 03/04/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-01 No dispute reported 06/30/2026 1249012821
Principal investigator 1 BioNTech SE $7,038.55 03/04/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012937
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77,513.63 03/04/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184156792
Principal investigator 1 Boehringer Ingelheim International GmbH $2,004.10 03/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703861
Principal investigator 1 Boehringer Ingelheim International GmbH $9,945.00 03/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703863
Principal investigator 1 Boehringer Ingelheim International GmbH $1,986.00 03/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703865
Principal investigator 1 Boehringer Ingelheim International GmbH $790.00 03/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703867
Principal investigator 1 Boehringer Ingelheim International GmbH $790.00 03/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703869
Principal investigator 1 Boehringer Ingelheim International GmbH $68.00 03/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703871
Principal investigator 1 Boehringer Ingelheim International GmbH $101.00 03/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703873
Principal investigator 1 Boehringer Ingelheim International GmbH $68.00 03/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703875
Principal investigator 1 Boehringer Ingelheim International GmbH $7,946.00 03/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703877
Principal investigator 1 Boehringer Ingelheim International GmbH $7,946.00 03/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703879
Principal investigator 1 Boehringer Ingelheim International GmbH $7,946.00 03/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703881
Principal investigator 1 Boehringer Ingelheim International GmbH $7,946.00 03/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703883
Principal investigator 1 Boehringer Ingelheim International GmbH $7,946.00 03/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703885
Principal investigator 1 Boehringer Ingelheim International GmbH $790.00 03/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703887
Principal investigator 1 Boehringer Ingelheim International GmbH $112.00 03/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703889
Principal investigator 1 Boehringer Ingelheim International GmbH $242.00 03/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703891
Principal investigator 1 Boehringer Ingelheim International GmbH $47.00 03/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703893
Principal investigator 1 Boehringer Ingelheim International GmbH $101.00 03/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703895
Principal investigator 1 Boehringer Ingelheim International GmbH $790.00 03/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703897
Principal investigator 1 Boehringer Ingelheim International GmbH $1,986.00 03/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703899
Principal investigator 1 Boehringer Ingelheim International GmbH $7.00 03/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703911
Principal investigator 1 Daiichi Sankyo Inc. $5,551.00 03/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389209
Principal investigator 1 Daiichi Sankyo Inc. $15.50 03/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389285
Principal investigator 1 Daiichi Sankyo Inc. $412.40 03/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389287
Principal investigator 1 Daiichi Sankyo Inc. $15.50 03/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389289
Principal investigator 1 Daiichi Sankyo Inc. $15.50 03/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389291
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 03/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577704
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 03/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577706
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703853
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220704151
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220704153
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704215
Principal investigator 1 Boehringer Ingelheim International GmbH $785.00 03/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
PhII in 2nd line pts with Her2+ tumors other than NSCLC No dispute reported 06/30/2026 1220704377
Principal investigator 1 Boehringer Ingelheim International GmbH $1,232.55 02/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704205
Principal investigator 1 Boehringer Ingelheim International GmbH $1,344.75 02/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704207
Principal investigator 1 Boehringer Ingelheim International GmbH $926.25 02/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704209
Principal investigator 1 Boehringer Ingelheim International GmbH $1,622.70 02/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704211
Principal investigator 1 Janssen Research & Development, LLC $32,362.00 02/28/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413875
Principal investigator 1 Amgen Inc. $1,331.92 02/25/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305) No dispute reported 06/30/2026 1246651095
Principal investigator 1 BeiGene, Ltd. $7,361.00 02/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190320410
Principal investigator 1 BioNTech SE $7,959.10 02/25/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-01 No dispute reported 06/30/2026 1249012819
Principal investigator 1 BioNTech SE $270.00 02/25/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012943
Principal investigator 1 BioNTech SE $1,979.00 02/25/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012945
Principal investigator 1 BioNTech SE $77.00 02/25/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012947
Principal investigator 1 BioNTech SE $211.00 02/25/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012949
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,318.50 02/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220996738
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $899.10 02/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220996740
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $24.00 02/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220996742
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $339.40 02/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220996858
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $182.50 02/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220996860
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $7.30 02/25/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220996862
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,453.40 02/25/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184155620
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,092.15 02/25/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184155622
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14,742.00 02/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220804985
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 02/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220804987
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $25,176.15 02/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220804989
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,981.95 02/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220804979
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 02/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220804981
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,914.00 02/22/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220804983
Principal investigator 1 Boehringer Ingelheim International GmbH $706.33 02/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703815
Principal investigator 1 Boehringer Ingelheim International GmbH $68.00 02/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703817
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 02/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703819
Principal investigator 1 Boehringer Ingelheim International GmbH $155.00 02/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703821
Principal investigator 1 Boehringer Ingelheim International GmbH $68.00 02/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703823
Principal investigator 1 Boehringer Ingelheim International GmbH $101.00 02/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703825
Principal investigator 1 Boehringer Ingelheim International GmbH $1,658.00 02/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703827
Principal investigator 1 Boehringer Ingelheim International GmbH $101.00 02/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703829
Principal investigator 1 Boehringer Ingelheim International GmbH $338.00 02/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703831
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 02/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703833
Principal investigator 1 Boehringer Ingelheim International GmbH $68.00 02/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703835
Principal investigator 1 Boehringer Ingelheim International GmbH $68.00 02/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703837
Principal investigator 1 Boehringer Ingelheim International GmbH $236.00 02/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703839
Principal investigator 1 Boehringer Ingelheim International GmbH $3,510.00 02/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703841
Principal investigator 1 Boehringer Ingelheim International GmbH $3,105.00 02/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703843
Principal investigator 1 Boehringer Ingelheim International GmbH $3,105.00 02/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703845
Principal investigator 1 Boehringer Ingelheim International GmbH $989.00 02/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703847
Principal investigator 1 Boehringer Ingelheim International GmbH $7.00 02/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703849
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.30 02/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220804975
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,093.00 02/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220804977
Principal investigator 1 Daiichi Sankyo Inc. $4,818.00 02/19/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389921
Principal investigator 1 Daiichi Sankyo Inc. $4,818.00 02/19/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389923
Principal investigator 1 Daiichi Sankyo Inc. $4,818.00 02/19/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389925
Principal investigator 1 Daiichi Sankyo Inc. $4,818.00 02/19/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389927
Principal investigator 1 Daiichi Sankyo Inc. $4,818.00 02/19/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389929
Principal investigator 1 Daiichi Sankyo Inc. $4,818.00 02/19/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389931
Principal investigator 1 Daiichi Sankyo Inc. $4,818.00 02/19/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389981
Principal investigator 1 BeiGene, Ltd. $340.00 02/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190324818
Principal investigator 1 BeiGene, Ltd. $785.00 02/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190324822
Principal investigator 1 BeiGene, Ltd. $966.08 02/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190324824
Principal investigator 1 BeiGene, Ltd. $16,839.00 02/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190325654
Principal investigator 1 BeiGene, Ltd. $1,980.00 02/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190325686
Principal investigator 1 BeiGene, Ltd. $2,614.44 02/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190325688
Principal investigator 1 BeiGene, Ltd. $2,385.00 02/18/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190325690
Principal investigator 1 PFIZER INC. $28,566.00 02/18/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228859338
Principal investigator 1 PFIZER INC. $17,407.32 02/18/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228859349
Principal investigator 1 PFIZER INC. $18,417.48 02/18/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228859356
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $322.75 02/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220804971
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $899.10 02/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220804973
Principal investigator 1 BeiGene USA, Inc. $1,008.00 02/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190321494
Principal investigator 1 BeiGene USA, Inc. $462.00 02/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190321496
Principal investigator 1 BeiGene USA, Inc. $733.00 02/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190321498
Principal investigator 1 BeiGene USA, Inc. $858.00 02/11/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190321500
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,699.20 02/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220805659
Principal investigator 1 Genentech, Inc. $90,155.00 02/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211681964
Principal investigator 1 BeiGene, Ltd. $25,838.16 02/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190322032
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $29,673.90 02/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220805347
Principal investigator 1 Daiichi Sankyo Inc. $8,500.00 02/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389173
Principal investigator 1 Daiichi Sankyo Inc. $3,980.00 02/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389185
Principal investigator 1 Daiichi Sankyo Inc. $6,249.00 02/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389187
Principal investigator 1 Daiichi Sankyo Inc. $2,970.00 02/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389189
Principal investigator 1 Daiichi Sankyo Inc. $3,015.00 02/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389193
Principal investigator 1 Daiichi Sankyo Inc. $8,647.00 02/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389197
Principal investigator 1 Daiichi Sankyo Inc. $2,557.00 02/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389199
Principal investigator 1 Daiichi Sankyo Inc. $2,557.00 02/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389201
Principal investigator 1 Daiichi Sankyo Inc. $5,397.00 02/07/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389205
Principal investigator 1 ABBVIE INC. $37,125.00 02/06/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
M22-128 - A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-4) No dispute reported 06/30/2026 1202449875
Principal investigator 1 BioNTech SE $3,444.70 02/05/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-01 No dispute reported 06/30/2026 1249012817
Principal investigator 1 BioNTech SE $8,959.45 02/05/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012935
Principal investigator 1 BeiGene, Ltd. $549.56 02/04/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190324820
Principal investigator 1 Janssen Research & Development, LLC $35,450.00 02/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175413797
Principal investigator 1 PFIZER INC. $3,039.00 02/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228859334
Principal investigator 1 PFIZER INC. $12,567.66 02/03/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228859482
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 02/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577700
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 02/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577702
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703851
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220704147
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220704149
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704203
Principal investigator 1 AstraZeneca UK Limited $57,039.00 01/31/2025 Non-covered Recipient Entity
VALKYRIE GLOBAL, INC
a phase 2,open label study to evaluate the safety,tolerability,pharmacokinetics,immunogenicity,and antitumor activity of volrustomig priming regimen in combination with other anticancer agents in participants with solid tumors evolve 01 No dispute reported 06/30/2026 1185552415
Principal investigator 1 BeiGene, Ltd. $47,160.00 01/30/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325320
Principal investigator 1 BioNTech SE $5,722.80 01/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012933
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $69,933.35 01/29/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184150046
Principal investigator 1 ABBVIE INC. $76.54 01/28/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202441722
Principal investigator 1 BeiGene, Ltd. $7,056.00 01/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190320408
Principal investigator 1 BeiGene, Ltd. $10,749.00 01/28/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1190325652
Principal investigator 1 Amgen Inc. $189,306.93 01/27/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy No dispute reported 06/30/2026 1246651098
Principal investigator 1 BeiGene, Ltd. $600.00 01/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320104
Principal investigator 1 Boehringer Ingelheim International GmbH $373.34 01/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703913
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 01/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703915
Principal investigator 1 Boehringer Ingelheim International GmbH $255.50 01/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703917
Principal investigator 1 Boehringer Ingelheim International GmbH $122.14 01/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703919
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 01/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703921
Principal investigator 1 Boehringer Ingelheim International GmbH $27.74 01/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703923
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $33,981.50 01/27/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804833
Principal investigator 1 BeiGene, Ltd. $15,720.00 01/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323642
Principal investigator 1 BeiGene, Ltd. $1,439.81 01/24/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323644
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $10,010.43 01/23/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220996830
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $144,975.04 01/23/2025 Non-covered Recipient Entity
Valkyrie Global, Inc
A Phase 1/1b First-in-human Study of BMS-986463 in Advanced Malignant Tumors No dispute reported 06/30/2026 1235992017
Principal investigator 1 Incyte Corporation $129.00 01/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610673
Principal investigator 1 Incyte Corporation $129.00 01/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610699
Principal investigator 1 Incyte Corporation $675.00 01/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610702
Principal investigator 1 Incyte Corporation $2,916.00 01/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610710
Principal investigator 1 Incyte Corporation $2,916.00 01/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610713
Principal investigator 1 Incyte Corporation $3,040.00 01/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610718
Principal investigator 1 Incyte Corporation $3,040.00 01/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610722
Principal investigator 1 Incyte Corporation $2,822.00 01/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610732
Principal investigator 1 Incyte Corporation $2,822.00 01/22/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240610736
Principal investigator 1 BeiGene, Ltd. $3,132.00 01/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190320406
Principal investigator 1 BioNTech SE $3,433.30 01/21/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012931
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,975.50 01/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804827
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,825.00 01/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804829
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,797.45 01/21/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials Inc
DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas No dispute reported 06/30/2026 1220804831
Principal investigator 1 PFIZER INC. $998.00 01/21/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228859502
Principal investigator 1 PFIZER INC. $3,039.00 01/21/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 No dispute reported 06/30/2026 1228859512
Principal investigator 1 BeiGene, Ltd. $15,720.00 01/20/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190323808
Principal investigator 1 BioNTech SE $6,510.35 01/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-01 No dispute reported 06/30/2026 1249012815
Principal investigator 1 BioNTech SE $1,072.15 01/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-01 No dispute reported 06/30/2026 1249012827
Principal investigator 1 BioNTech SE $8,491.10 01/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012929
Principal investigator 1 Incyte Corporation $329.00 01/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240610680
Principal investigator 1 Incyte Corporation $329.00 01/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240610683
Principal investigator 1 Incyte Corporation $3,449.00 01/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240610686
Principal investigator 1 Incyte Corporation $3,449.00 01/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240610691
Principal investigator 1 Incyte Corporation $2,882.30 01/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240610695
Principal investigator 1 Incyte Corporation $329.00 01/17/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation No dispute reported 06/30/2026 1240610743
Principal investigator 1 Daiichi Sankyo Inc. $4,818.00 01/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389829
Principal investigator 1 Daiichi Sankyo Inc. $4,818.00 01/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389893
Principal investigator 1 Daiichi Sankyo Inc. $4,818.00 01/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389895
Principal investigator 1 Daiichi Sankyo Inc. $4,818.00 01/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389897
Principal investigator 1 Daiichi Sankyo Inc. $4,818.00 01/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389899
Principal investigator 1 Daiichi Sankyo Inc. $4,818.00 01/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389901
Principal investigator 1 Daiichi Sankyo Inc. $4,818.00 01/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389903
Principal investigator 1 Daiichi Sankyo Inc. $4,818.00 01/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389905
Principal investigator 1 Daiichi Sankyo Inc. $4,818.00 01/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389907
Principal investigator 1 Daiichi Sankyo Inc. $4,818.00 01/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389909
Principal investigator 1 Daiichi Sankyo Inc. $6,724.00 01/15/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389971
Principal investigator 1 Daiichi Sankyo Inc. $1,620.00 01/13/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389177
Principal investigator 1 Daiichi Sankyo Inc. $62.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388755
Principal investigator 1 Daiichi Sankyo Inc. $50.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388757
Principal investigator 1 Daiichi Sankyo Inc. $74.70 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388759
Principal investigator 1 Daiichi Sankyo Inc. $74.70 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388761
Principal investigator 1 Daiichi Sankyo Inc. $74.70 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388763
Principal investigator 1 Daiichi Sankyo Inc. $74.70 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388765
Principal investigator 1 Daiichi Sankyo Inc. $41.70 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388767
Principal investigator 1 Daiichi Sankyo Inc. $41.70 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388769
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388771
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388773
Principal investigator 1 Daiichi Sankyo Inc. $41.70 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388775
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388777
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388779
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388781
Principal investigator 1 Daiichi Sankyo Inc. $41.70 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388783
Principal investigator 1 Daiichi Sankyo Inc. $41.70 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388785
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388787
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388789
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388791
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388793
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388795
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388797
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388799
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388801
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388803
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388805
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388807
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388809
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388811
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388813
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388815
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388817
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388819
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388821
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388823
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388825
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388827
Principal investigator 1 Daiichi Sankyo Inc. $62.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388829
Principal investigator 1 Daiichi Sankyo Inc. $62.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388831
Principal investigator 1 Daiichi Sankyo Inc. $195.60 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388833
Principal investigator 1 Daiichi Sankyo Inc. $195.60 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388835
Principal investigator 1 Daiichi Sankyo Inc. $62.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388837
Principal investigator 1 Daiichi Sankyo Inc. $62.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388839
Principal investigator 1 Daiichi Sankyo Inc. $62.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388841
Principal investigator 1 Daiichi Sankyo Inc. $62.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388843
Principal investigator 1 Daiichi Sankyo Inc. $77.50 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388861
Principal investigator 1 Daiichi Sankyo Inc. $77.50 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388863
Principal investigator 1 Daiichi Sankyo Inc. $77.50 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388865
Principal investigator 1 Daiichi Sankyo Inc. $13.65 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388903
Principal investigator 1 Daiichi Sankyo Inc. $515.50 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388905
Principal investigator 1 Daiichi Sankyo Inc. $345.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388907
Principal investigator 1 Daiichi Sankyo Inc. $41.70 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388919
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388925
Principal investigator 1 Daiichi Sankyo Inc. $567.05 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388927
Principal investigator 1 Daiichi Sankyo Inc. $77.50 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388929
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388931
Principal investigator 1 Daiichi Sankyo Inc. $100.30 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388935
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/10/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223388939
Principal investigator 1 BioNTech SE $5,535.00 01/09/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012941
Principal investigator 1 BeiGene, Ltd. $15,120.00 01/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190322054
Principal investigator 1 BeiGene, Ltd. $25,838.16 01/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190322056
Principal investigator 1 Daiichi Sankyo Inc. $2,970.00 01/08/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-324 No dispute reported 06/30/2026 1223389145
Principal investigator 1 Amgen Inc. $27,494.00 01/07/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda (Pembrolizumab) in Subjects With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1246651102
Principal investigator 1 BioNTech SE $6,367.85 01/07/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-01 No dispute reported 06/30/2026 1249012813
Principal investigator 1 BioNTech SE $19,281.20 01/07/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
BNT327-02 No dispute reported 06/30/2026 1249012927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $48,936.00 01/07/2025 Non-covered Recipient Entity
VALKYRIE CLINICAL TRIALS INC
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184146206
Principal investigator 1 BeiGene, Ltd. $2,240.00 01/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
AdvanTIG-205: A Phase 2, Randomized Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Previously Untreated Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1190320064
Principal investigator 1 BeiGene, Ltd. $3,360.00 01/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
AdvanTIG-205: A Phase 2, Randomized Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Previously Untreated Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1190324202
Principal investigator 1 BeiGene, Ltd. $603.00 01/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
AdvanTIG-205: A Phase 2, Randomized Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Previously Untreated Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1190324212
Principal investigator 1 BeiGene, Ltd. $2,904.00 01/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
AdvanTIG-205: A Phase 2, Randomized Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Previously Untreated Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1190324332
Principal investigator 1 BeiGene, Ltd. $3,521.00 01/06/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials, Inc
AdvanTIG-205: A Phase 2, Randomized Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Previously Untreated Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1190324340
Principal investigator 1 Boehringer Ingelheim International GmbH $3,105.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703771
Principal investigator 1 Boehringer Ingelheim International GmbH $989.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703773
Principal investigator 1 Boehringer Ingelheim International GmbH $2,160.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703775
Principal investigator 1 Boehringer Ingelheim International GmbH $312.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703777
Principal investigator 1 Boehringer Ingelheim International GmbH $473.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703779
Principal investigator 1 Boehringer Ingelheim International GmbH $725.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703781
Principal investigator 1 Boehringer Ingelheim International GmbH $5,777.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703783
Principal investigator 1 Boehringer Ingelheim International GmbH $6,878.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703785
Principal investigator 1 Boehringer Ingelheim International GmbH $790.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703787
Principal investigator 1 Boehringer Ingelheim International GmbH $3,510.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703789
Principal investigator 1 Boehringer Ingelheim International GmbH $3,105.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703791
Principal investigator 1 Boehringer Ingelheim International GmbH $3,105.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703793
Principal investigator 1 Boehringer Ingelheim International GmbH $725.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703795
Principal investigator 1 Boehringer Ingelheim International GmbH $989.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703797
Principal investigator 1 Boehringer Ingelheim International GmbH $5,777.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703799
Principal investigator 1 Boehringer Ingelheim International GmbH $408.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703801
Principal investigator 1 Boehringer Ingelheim International GmbH $2,028.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703803
Principal investigator 1 Boehringer Ingelheim International GmbH $2,028.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703805
Principal investigator 1 Boehringer Ingelheim International GmbH $2,028.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703807
Principal investigator 1 Boehringer Ingelheim International GmbH $3,510.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703809
Principal investigator 1 Boehringer Ingelheim International GmbH $3,105.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703811
Principal investigator 1 Daiichi Sankyo Inc. $379.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389831
Principal investigator 1 Daiichi Sankyo Inc. $6,818.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389833
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389835
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389837
Principal investigator 1 Daiichi Sankyo Inc. $2,943.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389839
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389933
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389935
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389937
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389939
Principal investigator 1 Daiichi Sankyo Inc. $2,801.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389941
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389943
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389945
Principal investigator 1 Daiichi Sankyo Inc. $4,500.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389947
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389949
Principal investigator 1 Daiichi Sankyo Inc. $4,188.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389951
Principal investigator 1 Daiichi Sankyo Inc. $379.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389953
Principal investigator 1 Daiichi Sankyo Inc. $2,943.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389979
Principal investigator 1 Daiichi Sankyo Inc. $4,185.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389983
Principal investigator 1 Daiichi Sankyo Inc. $4,725.00 01/03/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS7300-203 No dispute reported 06/30/2026 1223389985
Principal investigator 1 Daiichi Sankyo Inc. $41.70 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389217
Principal investigator 1 Daiichi Sankyo Inc. $41.70 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389219
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389221
Principal investigator 1 Daiichi Sankyo Inc. $41.70 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389223
Principal investigator 1 Daiichi Sankyo Inc. $41.70 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389225
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389227
Principal investigator 1 Daiichi Sankyo Inc. $4.40 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389229
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389231
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389233
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389235
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389237
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389239
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389241
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389243
Principal investigator 1 Daiichi Sankyo Inc. $75.00 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389245
Principal investigator 1 Daiichi Sankyo Inc. $85.40 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389247
Principal investigator 1 Daiichi Sankyo Inc. $74.50 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389249
Principal investigator 1 Daiichi Sankyo Inc. $257.75 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389251
Principal investigator 1 Daiichi Sankyo Inc. $4.25 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389253
Principal investigator 1 Daiichi Sankyo Inc. $120.75 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389255
Principal investigator 1 Daiichi Sankyo Inc. $9.75 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389257
Principal investigator 1 Daiichi Sankyo Inc. $15.50 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389259
Principal investigator 1 Daiichi Sankyo Inc. $15.50 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389261
Principal investigator 1 Daiichi Sankyo Inc. $15.50 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389263
Principal investigator 1 Daiichi Sankyo Inc. $15.50 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389265
Principal investigator 1 Daiichi Sankyo Inc. $15.50 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389267
Principal investigator 1 Daiichi Sankyo Inc. $15.50 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389269
Principal investigator 1 Daiichi Sankyo Inc. $15.50 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389271
Principal investigator 1 Daiichi Sankyo Inc. $17.25 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389273
Principal investigator 1 Daiichi Sankyo Inc. $50.15 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389275
Principal investigator 1 Daiichi Sankyo Inc. $15.50 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389277
Principal investigator 1 Daiichi Sankyo Inc. $15.50 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389279
Principal investigator 1 Daiichi Sankyo Inc. $15.50 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389281
Principal investigator 1 Daiichi Sankyo Inc. $20.85 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389283
Principal investigator 1 Daiichi Sankyo Inc. $31.00 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389293
Principal investigator 1 Daiichi Sankyo Inc. $15.50 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389295
Principal investigator 1 Daiichi Sankyo Inc. $41.70 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389297
Principal investigator 1 Daiichi Sankyo Inc. $20.85 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389299
Principal investigator 1 Daiichi Sankyo Inc. $2.20 01/02/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
DS3201-330 No dispute reported 06/30/2026 1223389301
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 01/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577708
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 01/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577710
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220703813
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220704155
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours No dispute reported 06/30/2026 1220704157
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Valkyrie Clinical Trials
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220704217